Torsten Haferlach

Torsten Haferlach's AcademicInfluence.com Rankings

Torsten Haferlach

Philosophy

#6309

Historical Rank

Logic

#2306

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Torsten Haferlach Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Torsten Haferlach's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Frequent pathway mutations of splicing machinery in myelodysplasia (2011) (1799)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes (2013) (1219)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. (2002) (1010)
BRAF mutations in hairy-cell leukemia. (2011) (763)
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. (2005) (750)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018) (689)
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. (2012) (567)
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. (2010) (566)
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. (2011) (564)
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin (2008) (529)
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) (1995) (513)
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. (2014) (513)
AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia (2001) (502)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. (2007) (477)
Prognostic score including gene mutations in chronic myelomonocytic leukemia. (2013) (467)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. (2006) (387)
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. (2008) (383)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms (2022) (373)
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. (1999) (345)
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia (2012) (343)
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping (2007) (331)
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms (2012) (325)
G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft (1994) (324)
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. (2003) (322)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. (2009) (321)
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. (2009) (319)
Dynamics of clonal evolution in myelodysplastic syndromes (2016) (311)
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases (2002) (300)
Implications of NRAS mutations in AML: a study of 2502 patients. (2006) (299)
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. (2010) (299)
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML (2000) (293)
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML (2004) (287)
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). (2012) (285)
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles (2002) (283)
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. (2003) (281)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes (2010) (280)
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. (2006) (273)
EZH2 mutations are frequent and represent an early event in follicular lymphoma. (2013) (261)
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. (2011) (259)
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. (2004) (252)
A novel hierarchical prognostic model of AML solely based on molecular mutations. (2012) (248)
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients (2014) (241)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype (2009) (236)
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. (1995) (234)
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. (2011) (232)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. (2017) (226)
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? (2011) (224)
Landscape of TET2 mutations in acute myeloid leukemia (2012) (222)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). (2020) (219)
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. (2003) (219)
Global approach to the diagnosis of leukemia using gene expression profiling. (2005) (217)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. (2011) (213)
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. (2006) (211)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. (2016) (209)
Comprehensive mutational profiling in advanced systemic mastocytosis. (2013) (208)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype (2008) (203)
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome (2013) (197)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. (2010) (195)
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis (2015) (192)
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. (2006) (190)
Monitoring of minimal residual disease in acute myeloid leukemia (2005) (187)
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome (2014) (184)
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients (2001) (184)
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. (2003) (183)
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia (2005) (182)
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia (2000) (172)
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. (2009) (170)
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia (2009) (170)
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. (2009) (169)
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile (2005) (169)
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. (2015) (166)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases (2011) (165)
Molecular characterization of acute leukemias by use of microarray technology (2003) (161)
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. (2013) (159)
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations (2013) (157)
An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase (2008) (156)
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma (2007) (154)
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. (2000) (153)
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms (2015) (151)
The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL (2013) (150)
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases (2017) (146)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis (2016) (145)
The role of different genetic subtypes of CEBPA mutated AML (2014) (144)
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. (2007) (142)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions (2017) (141)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance (2011) (141)
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML (2010) (141)
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field (2012) (140)
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. (2004) (137)
Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease (2002) (137)
Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. (1996) (135)
Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation [letter] (1993) (129)
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. (2009) (126)
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status (2014) (121)
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. (2009) (121)
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. (2004) (120)
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. (2004) (120)
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia (2011) (119)
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. (2007) (119)
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. (2014) (115)
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes (2016) (115)
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories (2011) (114)
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24‐color FISH (2002) (114)
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. (2021) (112)
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients (2004) (112)
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event (2014) (110)
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome (2014) (109)
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. (2022) (109)
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. (2004) (107)
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. (2002) (107)
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). (2010) (106)
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial (2018) (103)
Detailed analysis of FLT3 expression levels in acute myeloid leukemia. (2005) (101)
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG (2009) (99)
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes (2005) (99)
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease (2014) (99)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (2020) (98)
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine (2004) (98)
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients (1996) (97)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features (2009) (91)
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis (2013) (90)
Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis (2013) (89)
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. (2016) (88)
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. (2005) (88)
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia (2014) (88)
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (88)
Molecular genetics in acute myeloid leukemia (2010) (87)
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics (1999) (86)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. (2003) (86)
Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate (2003) (85)
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E (2006) (85)
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. (1993) (85)
The role of multiparameter flow cytometry for disease monitoring in AML. (2010) (85)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. (2020) (83)
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia (2008) (83)
STAT3 mutations are highly specific for large granular lymphocytic leukemia (2013) (82)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data (2012) (81)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. (2017) (81)
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. (2008) (81)
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities (2000) (81)
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene (2006) (80)
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype (2009) (80)
Landmark analysis of DNMT3A mutations in hematological malignancies (2013) (80)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis (2012) (80)
FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia (2004) (79)
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. (2011) (79)
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype (2005) (79)
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome (2010) (79)
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. (2005) (78)
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions (2019) (78)
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies (2010) (78)
Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. (2003) (76)
Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings (2004) (76)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. (2011) (76)
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% (2014) (76)
Recurrent CDKN1B (p27) mutations in hairy cell leukemia. (2015) (75)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party (2021) (75)
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q (2005) (75)
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients (2013) (74)
Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. (2011) (74)
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis (1997) (74)
Genomic subtyping and therapeutic targeting of acute erythroleukemia (2019) (73)
CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS (2015) (73)
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy (2002) (73)
Color Atlas of Hematology: Practical Microscopic and Clinical Diagnosis (2004) (72)
Subtype-specific patterns of molecular mutations in acute myeloid leukemia (2017) (72)
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera (2009) (72)
Modern diagnostics in acute leukemias. (2005) (72)
Chromothripsis in acute myeloid leukemia: biological features and impact on survival (2017) (72)
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. (2017) (72)
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. (2004) (72)
Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis (2014) (71)
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase (2015) (71)
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis (2009) (71)
Impact of FLT3 mutations and promyelocytic leukaemia‐breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia (2005) (71)
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 (2000) (71)
The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization. (1996) (70)
Cytogenetics in acute myeloid leukemia (2002) (70)
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups (2014) (69)
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPα DNA binding via leucine zipper domain interaction (2003) (68)
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). (2020) (68)
Discovery of epigenetically silenced genes in acute myeloid leukemias (2007) (68)
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia (2011) (67)
AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions (2010) (67)
Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. (1991) (66)
BCOR regulates myeloid cell proliferation and differentiation (2016) (66)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes (2021) (66)
Which compartments are involved in Philadelphia‐chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques (1997) (66)
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. (2020) (66)
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. (2012) (66)
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO (2006) (66)
Correlation of protein expression and gene expression in acute leukemia (2003) (66)
Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways (2010) (65)
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. (2001) (65)
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD) (2016) (65)
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA (2011) (65)
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm (2017) (64)
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information (2005) (64)
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations (2015) (63)
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia (2014) (61)
Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. (1993) (61)
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia (2011) (61)
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms (2013) (60)
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. (2011) (60)
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL (2018) (59)
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature (2018) (59)
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach (2007) (59)
Robustness of amplicon deep sequencing underlines its utility in clinical applications. (2013) (59)
Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia (2010) (57)
Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL (2012) (57)
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. (2012) (57)
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. (1996) (57)
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics (2012) (56)
CEBPA double‐mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis (2013) (56)
Next‐generation sequencing – feasibility and practicality in haematology (2013) (56)
Genetic characterization of T‐PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker (2016) (56)
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. (2004) (56)
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. (2010) (56)
Dependence of age-specific incidence of acute myeloid leukemia on karyotype. (2001) (56)
Application of an NGS‐based 28‐gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera (2016) (55)
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations (2011) (55)
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients (2002) (54)
CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B‐cell chronic lymphocytic leukaemia cells (2002) (54)
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. (2018) (53)
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks (2006) (53)
Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation (2003) (53)
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters (2010) (53)
SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis (2013) (52)
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category (2009) (52)
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. (2011) (51)
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients (2007) (51)
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. (2015) (51)
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis (2019) (51)
Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis (2014) (51)
Acute myeloid leukemia with mutated nucleophosmin ( NPM 1 ) : is it a distinct entity ? (2011) (51)
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha (2005) (51)
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers (2007) (50)
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events (2012) (50)
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group (2012) (50)
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS) (2016) (50)
Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome (2014) (49)
High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia (2013) (49)
Quantitative comparison of microarray experiments with published leukemia related gene expression signatures (2009) (49)
A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (2018) (49)
Gene expression profiling as a tool for the diagnosis of acute leukemias. (2003) (48)
Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia (2012) (48)
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells (2011) (48)
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes (2005) (47)
Treatment of older patients with AML. (2005) (47)
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice (2008) (46)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia (2016) (46)
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact (2014) (46)
Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms. (2019) (46)
An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling (2011) (46)
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure (2011) (46)
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia (2014) (46)
PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells. (2012) (45)
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis (2010) (45)
BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia (2010) (45)
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML (2019) (45)
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. (2005) (44)
Pattern robustness of diagnostic gene expression signatures in leukemia (2005) (43)
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. (2004) (43)
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. (2018) (42)
Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics (2019) (42)
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients (2005) (42)
Consequences of mutant TET2 on clonality and subclonal hierarchy (2018) (42)
IDH 1 mutations are detected in 6 . 6 % of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM 1 status (2010) (42)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia (2016) (41)
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty (2010) (41)
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. (2010) (40)
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML (2011) (40)
The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia (2012) (40)
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery (2018) (40)
Integration of next-generation sequencing into clinical practice: are we there yet? (2012) (40)
Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies (1996) (39)
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes (2019) (39)
Evaluation of complete disease remission in acute myeloid leukemia (2006) (39)
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis (2008) (39)
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. (1996) (39)
Staging systems for multiple myeloma: a comparison (1985) (39)
Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups (2006) (39)
Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation (1997) (39)
Molecular diagnostics in acute leukemias (2009) (39)
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML (2007) (39)
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 (2013) (38)
Clinical Utility of Multiparameter Flow Cytometry in the Diagnosis of 1013 Patients with Suspected Myelodysplastic Syndrome: Correlation to Cytomorphology, Cytogenetic, and Clinical Data. (2009) (38)
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period (2008) (37)
Gene expression profiling in sarcomas. (2007) (36)
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia (2016) (36)
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. (2003) (36)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 (2018) (36)
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia (2001) (36)
The role of the RAS pathway in iAMP21-ALL (2016) (36)
Acute myeloid leukemia: treatment over 60. (2002) (35)
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms (2011) (35)
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set (2021) (35)
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms (2018) (34)
Postallogeneic monitoring with molecular markers detected by pretransplant next‐generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms (2014) (34)
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase (2017) (34)
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes (2012) (34)
Activating CBL mutations are associated with a distinct MDS/MPN phenotype (2012) (34)
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics (2013) (33)
Insight into the molecular pathogenesis of myeloid malignancies (2007) (33)
Correlation of flow cytometrically determined expression of ZAP‐70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia (2009) (33)
The power and potential of integrated diagnostics in acute myeloid leukaemia (2019) (32)
Several lymphoma‐specific genetic events in parallel can be found in mature B‐cell neoplasms (2011) (32)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes (2017) (32)
Complex Landscape of Alternative Splicing in Myeloid Neoplasms (2020) (31)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes (2020) (31)
Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML (2018) (31)
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases (2012) (31)
AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes (2009) (31)
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose (2019) (31)
Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment (2010) (31)
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms (2016) (30)
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1 (2010) (30)
Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing (2018) (30)
The use of housekeeping genes for real-time PCR-based quantification of fusion gene transcripts in acute myeloid leukemia (2004) (30)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia (2015) (30)
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). (2006) (30)
Quantification of rare NPM1 mutation subtypes by digital PCR (2014) (30)
Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. (2005) (29)
Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. (2021) (29)
ICON: Eosinophil Disorders (2012) (29)
Germline variants drive myelodysplastic syndrome in young adults (2021) (29)
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. (2005) (28)
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases (2007) (28)
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML (2007) (28)
Mutations of the TP53 Gene Occur in 13.4% of Acute Myeloid Leukemia and Are Strongly Associated with a Complex Aberrant Karyotype. (2006) (28)
Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12) (1998) (28)
New insights into the biology of Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia using a combination of May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques at the single cell level (1997) (28)
The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia (2016) (28)
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments (2006) (28)
Acute myeloid leukaemia (AML): treatment of the older patient. (2001) (28)
Morphological and cytochemical findings in 150 cases of T‐lineage acute lymphoblastic leukaemia in adults (1997) (27)
Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia (2015) (27)
WHO classification of myeloid neoplasms and leukemia. (2010) (27)
Genetic classification of acute myeloid leukemia (AML). (2004) (27)
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases (2012) (27)
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. (2004) (27)
Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia (2011) (27)
A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping (2001) (26)
D324N single‐nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias (2006) (26)
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. (2019) (26)
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow (2012) (26)
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B‐cell neoplasms (2010) (26)
AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients. (2015) (26)
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele (2012) (26)
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells (2011) (26)
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO (2008) (25)
Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia (2007) (25)
The Molecular Pathology of Myelodysplastic Syndrome (2018) (25)
Mutational profiling in patients with MDS: ready for every-day use in the clinic? (2015) (25)
Current status of gene expression profiling in the diagnosis and management of acute leukaemia (2009) (25)
Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene (2014) (25)
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia (2011) (24)
Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases (2012) (24)
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia. (2002) (24)
Near-tetraploid acute myeloid leukemias: an EGIL retrospective study of 25 cases (2006) (24)
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. (2012) (24)
Color Atlas of Hematology (2004) (24)
Leukemia diagnosis: today and tomorrow (2015) (24)
MANGANESE deficiency. (2022) (24)
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement. (2003) (23)
Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies. (2010) (23)
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. (2006) (23)
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. (2010) (23)
Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B‐CLL) and its genetic characterization (2014) (23)
Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. (2016) (22)
Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing (2018) (22)
Gene expression profiling in acute myeloid leukaemia (AML). (2009) (22)
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q (2015) (22)
Gene-expression profiling in acute myeloid leukemia. (2004) (22)
R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing data (2011) (22)
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. (2021) (22)
Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases (2013) (22)
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) (2008) (22)
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. (2008) (22)
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo (2020) (22)
The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML‐RARα in APL (2014) (21)
Expression of IGFBP7 in acute leukemia is regulated by DNA methylation (2011) (21)
Identification and functional characterization of imatinib‐sensitive DTD1‐PDGFRB and CCDC88C‐PDGFRB fusion genes in eosinophilia‐associated myeloid/lymphoid neoplasms (2014) (21)
The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? (2020) (21)
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis (2017) (21)
How artificial intelligence might disrupt diagnostics in hematology in the near future (2021) (21)
BRCC3 mutations in myeloid neoplasms (2015) (21)
A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene (2013) (21)
Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. (2020) (21)
Analysis of progenitor cell involvement in B‐CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level (1999) (21)
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse (2019) (20)
NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? (2008) (20)
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia. (2001) (20)
Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse (2017) (20)
Hematologist‐Level Classification of Mature B‐Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data (2020) (20)
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT) (2004) (20)
The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group (2008) (20)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes (2021) (20)
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal☆ (2017) (20)
Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients (2015) (20)
The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories (2012) (19)
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies (2021) (19)
Glass slide smears are a suitable source for RT‐PCR‐based analysis of chromosomal aberrations in leukaemias (1996) (19)
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes (2009) (19)
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. (2020) (19)
Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine (2015) (19)
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia (2015) (19)
Clinical utility of whole-genome sequencing in precision oncology. (2021) (18)
Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing (2014) (18)
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile (2018) (18)
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients (2012) (18)
MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients (2016) (18)
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration (2021) (18)
High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). (1991) (18)
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies (2018) (18)
EZH2 mutations and their association with PICALM‐MLLT10 positive acute leukaemia (2012) (18)
Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients (2018) (17)
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes (2015) (17)
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis (2019) (17)
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. (2020) (17)
Corrigendum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (Leukemia (2016) 30 (1672-1681) DOI: 10.1038/leu.2016.69) (2016) (17)
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. (2012) (17)
Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia (2012) (17)
Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. (2021) (16)
A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongen and multiple other molecular aberrations (2005) (16)
BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importance (2017) (16)
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. (2020) (16)
Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. (2022) (16)
Clinical relevance of clonal hematopoiesis in the oldest-old population. (2021) (16)
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML (2021) (16)
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside‐based treatment regimens in acute myeloid leukaemia with a high proliferative activity (2000) (16)
Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity (2009) (16)
Molecular genetics in myelodysplastic syndromes. (2012) (16)
Impact of integrating clinical and genetic information (2001) (16)
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all‐trans‐retinoic acid (2003) (15)
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML (2010) (15)
Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases (2018) (15)
Gene expression profiling for the diagnosis of acute leukaemia (2006) (15)
Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia (2016) (15)
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events. (2005) (15)
Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions (2016) (15)
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. (2010) (15)
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups (2013) (15)
The kinetics of relapse in DEK‐NUP214‐positive acute myeloid leukemia patients (2015) (15)
Mixed Phenotype Acute Leukemia, T/Myeloid, NOS (MPAL-TM) Has a High DNMT3A Mutation Frequency and Carries Further Genetic Features of Both AML and T-ALL: Results of a Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes (2012) (15)
Interactive diagnostics in the indication to allogeneic SCT in AML (2009) (15)
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia (2012) (15)
Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN (2016) (15)
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo‐1) and Fas Ligand (CD178) expression (2002) (14)
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. (2007) (14)
Should clinical hematologists put their microscopes on eBay? (2014) (14)
More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity? (1996) (14)
Automated morphological analysis of bone marrow cells in microscopic images for diagnosis of leukemia: nucleus-plasma separation and cell classification using a hierarchical tree model of hematopoesis (2016) (14)
ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion (2018) (14)
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern (2019) (14)
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary? (2000) (14)
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia (2006) (14)
Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias. (2012) (14)
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. (2012) (14)
Three Steps to the Diagnosis of Adult Ph-like ALL (2015) (14)
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. (2013) (14)
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients (2016) (14)
IDH1-R132 changes vary according to NPM1 and other mutations status in AML (2019) (13)
Next-generation diagnostics for precision oncology: preanalytical considerations, technical challenges, and available technologies. (2020) (13)
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia (2016) (13)
MYC rearranged B-cell neoplasms: Impact of genetics on classification. (2016) (13)
Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. (1997) (13)
Multiparameter flow cytometry reveals myelodysplasia‐related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms (2013) (13)
Towards a pathogenesis-oriented therapy of acute myeloid leukemia. (2005) (13)
Myeloid leukemia with transdifferentiation plasticity developing from T‐cell progenitors (2016) (13)
A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence (2019) (12)
Detection of Three Different MPLW515 Mutations in 10.1% of All JAK2 V617 Unmutated ET and 9.3% of All JAK2 V617F Unmutated OMF: A Study of 387 Patients. (2007) (12)
Moderne Verfahren in der Leukämiediagnostik (2002) (12)
Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. (2009) (12)
A decade with whole exome sequencing in haematology (2020) (12)
Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic Mastocytosis (2015) (12)
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). (2006) (12)
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. (2021) (12)
Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH) (2004) (12)
Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease (2018) (11)
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2021) (11)
A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment (2008) (11)
Relapse assessment following allogeneic SCT in patients with MDS and AML (2014) (11)
AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects. (1995) (11)
Malignant Transformation Involving CXXC4 Mutations Identified in a Leukemic Progression Model of Severe Congenital Neutropenia (2020) (11)
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics (2011) (11)
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH). (2009) (11)
Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia (2016) (11)
The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers (2015) (11)
Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia (2011) (11)
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations (2019) (11)
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. (2011) (11)
Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. (2010) (11)
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia (2017) (11)
VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice (2016) (11)
Risk-adapted therapy of AML: the AMLCG experience. (2004) (11)
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo (1993) (11)
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias (2006) (11)
Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies. (2009) (11)
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases (2012) (10)
Subgroup specific therapy effects in AML: AMLCG data. (2004) (10)
The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops (2021) (10)
A Generic Concept for Large-scale Microarray Analysis Dedicated to Medical Diagnostics (2006) (10)
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations (2021) (10)
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. (2019) (10)
Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond (2021) (10)
Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives. (1997) (10)
Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients (2020) (10)
Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia (2020) (10)
German Multicenter Study Group for Adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results (2002) (9)
Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1. (2014) (9)
Analytical Demands to Use Whole-Genome Sequencing in Precision Oncology. (2021) (9)
TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee (2014) (9)
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. (2010) (9)
Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study (2009) (9)
Multiple myeloma first presenting as cutaneous plasmacytoma. (1996) (9)
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes (2020) (9)
Remission induction therapy: the more intensive the better? (2001) (9)
Detailed molecular analysis and evaluation of prognosis in cases with high grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (2018) (9)
Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. (2012) (9)
Mutations of the TP53 Gene Play an Important Role in the Pathogenesis of Acute Myeloid Leukemia with Complex Aberrant Karyotype. (2004) (9)
Classification of Acute Leukemias (2003) (9)
Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome (2013) (9)
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes (2022) (9)
Germline DDX41 mutations define a unique subtype of myeloid neoplasms. (2022) (9)
TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes (2021) (8)
Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine. (2003) (8)
Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype (2013) (8)
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease (1993) (8)
Prognostic Impact and Landscape of NOTCH 1 Mutations in Chronic Lymphocytic Leukemia ( CLL ) : a Study on 852 Patients Letter to the Editor Chronic lymphocytic leukemia (2013) (8)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS . (2009) (8)
Automated classification of bone marrow cells in microscopic images for diagnosis of leukemia: a comparison of two classification schemes with respect to the segmentation quality (2015) (8)
Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance (2010) (8)
Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia (2021) (8)
Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia (2016) (8)
New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level (2001) (8)
IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients (2009) (8)
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. (1993) (8)
ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome (2011) (8)
Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. (2007) (8)
Gene Expression Profiling as a Diagnostic Tool in Acute Myeloid Leukemia (2004) (8)
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. (2022) (8)
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age (2022) (8)
Evaluation of BM cytomorphology after allo-SCT in patients with AML (2012) (8)
“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing? (2019) (8)
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations (2016) (8)
Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis (2016) (8)
More than a fusion gene: the RUNX1-RUNX1T1 AML. (2019) (8)
Discussion of the applicability of microarrays: profiling of leukemias. (2009) (7)
Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML (2013) (7)
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia. (2005) (7)
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes (2021) (7)
Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count (2020) (7)
PTPN 2 negatively regulates oncogenic JAK 1 in T-cell acute lymphoblastic leukemia (2011) (7)
SRSF2 is Mutated in 47.2% (77/163) of Chronic Myelomonocytic Leukemia (CMML) and Prognostically Favorable in Cases with Concomitant RUNX1 mutations (2011) (7)
[WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)]. (2002) (7)
Fifty-nine Cases of Acute Myeloid Leukemia with Inversion inv(16) (p13q22): Do Additional Chromosomal Aberrations Influence Prognosis? (1997) (7)
Role of gene expression profiling for diagnosing acute leukemias. (2005) (7)
Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology. (2021) (7)
A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling. (2005) (7)
WGS and WTS in leukaemia: A tool for diagnostics? (2020) (7)
Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival (2019) (7)
Chromosome Banding Analysis, FISH and RT-PCR Performed in Parallel in Hypereosinophilic Syndrome Establishes the Diagnosis of Chronic Eosinophilic Leukemia in 22% of Cases: A Study on 40 Patients. (2004) (7)
Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial. (2009) (7)
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population (2020) (7)
Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes (2022) (7)
The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability (2018) (7)
RT-PCR-Based MRD Detection in NPM1 Mutated AML: A Prospective Follow-Up Study in 130 Patients. (2007) (6)
Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. (2013) (6)
Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients (2010) (6)
Monitoring of Minimal Residual Disease Using Next-Generation Deep-Sequencing in 460 Acute Myeloid Leukemia Cases identifies RUNX1 Mutated Patients with Resistant Disease (2011) (6)
Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. (2021) (6)
Screening for TP53 Mutations Identifies Chronic Lymphocytic Leukemia Patients with Rapid Disease Progression. (2007) (6)
Semiquantitative reverse transcription polymerase chain reaction analysis for detection of bcr/abl rearrangement using RNA extracts from bone marrow aspirates compared with glass slide smears after 0, 2 and 4 d of storage (2001) (6)
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk (2022) (6)
Hämatologische Erkrankungen (2020) (6)
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (6)
Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations (2016) (6)
In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML (2014) (6)
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing (2021) (6)
Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family (2009) (6)
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia. (2007) (6)
Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations (2019) (6)
STAT3 Mutations in Large Granular Lymphocytic Leukemia (2012) (6)
Hematologic malignancies : myelodysplastic syndromes (2006) (6)
RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia (2009) (6)
Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia (2017) (6)
Cytogenetic Clonal Evolution in MDS Is Associated with Shifts towards Unfavorable Karyotypes According to IPSS and Shorter Overall Survival: A Study on 988 MDS Patients Studied Sequentially by Chromosome Banding Analysis (2011) (6)
Post‐transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm (2012) (6)
Therapeutic outcome in prognostic subgroups of de-novo acute myeloid leukemia (AML) and the role of the age factor. A study in 1834 patients of 16 to 84 years (2005) (6)
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia (2005) (6)
SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients (2012) (6)
Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia (2019) (6)
Knowledge transfer to enhance the performance of deep learning models for automated classification of B cell neoplasms (2021) (5)
Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA (2019) (5)
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). (2021) (5)
Blastic transformation of BCR‐ABL1 positive chronic myeloid leukaemia through acquisition of CBFB‐MYH11 and mutant KIT (2020) (5)
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions (2021) (5)
Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. (2004) (5)
Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD (2017) (5)
Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia (2012) (5)
Chromothripsis in Acute Myeloid Leukemia: biological features and impact on survival (2017) (5)
[Modern techniques in leukemia diagnosis]. (2002) (5)
Classification and Staging of Myelodysplastic Syndromes (2013) (5)
Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations (2015) (5)
Lokalisierung von Knochenmarkzellen für die automatisierte morphologische Analyse von Knochenmarkpräparaten (2014) (5)
An international multi-center study to assess the clinical accuracy of the molecular subclassification of leukemia by gene expression profiling. (2006) (5)
Evaluation of BM cytomorphology after allo-SCT in patients with MDS (2013) (5)
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms (2019) (5)
The Role of Different Genetic Subtypes In CEBPA Mutated AML (2010) (5)
Modern diagnostics in chronic myeloproliferative diseases (CMPDs). (2004) (5)
Genome Sequencing in Myeloid Cancers. (2021) (5)
Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms (2020) (5)
[Problems of intravenous urography in patients with plasmocytoma]. (1983) (5)
Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis (2016) (5)
Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse (1993) (5)
[Diagnostics of acute leukemias: interaction of phenotypic and genetic methods]. (2012) (5)
Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis (2019) (5)
Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23 (2012) (5)
Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study (2013) (4)
An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma (2018) (4)
Another piece of the AML puzzle. (2013) (4)
The Potential of Molecular Genetic Analysis for Diagnostic and Prognostic Decision Making in Clonal Cytopenia of Undetermined Significance (CCUS) and MDS - a Study on 576 Patients (2020) (4)
Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation? (1996) (4)
Correlation of Flow Cytometrically Determined Expression of ZAP-70 Using Two Different Antibodies with IgVH Mutation Status and Cytogenetics in 539 Patients with Chronic Lymphocytic Leukemia. (2006) (4)
European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe (2007) (4)
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics (2022) (4)
New insights into the biology of acute myeloid leukemia and their impact on treatment. (2003) (4)
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis (2022) (4)
The ParaHox gene Cdx4 induces acute erythroid leukemia in mice. (2019) (4)
AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions. (2009) (4)
The benefit of population-based studies for older patients with acute myeloid leukemia (2012) (4)
NRAS mutations in AML: biology, cytogenetics, and prognosis a study on 2502 patients (2006) (4)
The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia (2020) (4)
S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS (2019) (4)
A Novel Machine Learning Based in silico Pathogenicity Predictor for Missense Variants in a Hematological Setting (2019) (4)
RUNX1 Mutations in Normal Karyotype MDS Cooperate with Class I Mutations in the Progression to S-AML Following MDS. (2008) (4)
Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia Short title: Genetic alterations in myelodysplasia with HCT (2017) (4)
MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations (2016) (4)
PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2019) (4)
CML Patients with Resistance to Tyrosine Kinase Inhibitors and without BCR-ABL1 Resistance Mutation Frequently Carry Other Gene Mutations (2014) (4)
Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases (2014) (4)
Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes (2019) (4)
Gene Expression Profiling in AML and MDS Identifies Genes Located on 5q Which Are Consistently Lower Expressed in Cases with 5q Deletion as Compared to Cases with Normal Karyotype. (2004) (4)
RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired (2008) (4)
Quantitative Analysis of AML1-ETO Fusion Transcripts in t(8;21) Positive AML Using Real-Time RT-PCR (2002) (4)
Mutations in the JAK2 and MPL Genes and their Correlation to Clinical Parameters in Patients with Chronic Myeloproliferative Disease (2009) (4)
RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome (2019) (4)
C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation (2018) (4)
Older Age Is An Independent Risk Factor in AML (2008) (4)
Taschenatlas der Hämatologie (2002) (4)
Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. (2005) (4)
Evidence of clonality in cases of hypereosinophilia of undetermined significance (2019) (4)
Minimal Residual Disease in Patients with Acute Myeloid Leukemia Quantified by Multiparameter Flow Cytomety and Quantitative RT-PCR Is an Independent Prognostic Parameter. (2004) (4)
Erythroblastic synartesis in a patient initially diagnosed with myelodysplastic syndrome (2005) (4)
First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing (2012) (4)
Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML (2012) (4)
Molecular Analyses of MDS/MPN Overlap Entities According to WHO Classification Reveal a Distinct Molecular Pattern for MDS/MPN, Unclassifiable (2014) (4)
Quantitative reverse transcriptase-polymerase chain reaction in AML with t(8;21)(q22;q22). (2001) (4)
Low CD62L- expression in acute myeloid leukemia (AML) correlates with a bad cytogenetic risk (2001) (4)
Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia (2019) (4)
PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML (2015) (3)
“Clinical and Molecular Heterogeneity of Eosinophilia-Associated Myeloproliferative Neoplasms with a Translocation t(5;12)”. (2009) (3)
Artificial intelligence in hematological diagnostics: Game changer or gadget? (2022) (3)
Determination of Minimal Residual Disease in Patients with Acute Myeloid Leukemia by Multiparameter Flow Cytometry: Prognostic Impact at Different Checkpoints. (2004) (3)
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care. (2022) (3)
Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes (2013) (3)
RT-PCR in Diagnostics and Monitoring of Acute Myeloid (2001) (3)
Severe idiopathic erythroblastic synartesis: successful treatment with the anti‐CD20 monoclonal antibody rituximab (2010) (3)
TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia (2019) (3)
A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase-Deficient Cells in Myeloid Neoplasms. (2021) (3)
Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms (2018) (3)
DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML (2014) (3)
FISH-Diagnostik bei hämatologischen Neoplasien FISH diagnostics in hematological malignancies (2005) (3)
A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML (2020) (3)
High Membrane Cholesterol in CLL B-Cells and Differential Expression of Cholesterol Synthesis Genes in IG GENE- Unmutated vs Mutated Cells (2012) (3)
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2 (2017) (3)
Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients (2019) (3)
Categorizing Molecular Mutations in MDS and AML (2015) (3)
[Analysis of prognostic factors in plasmacytoma]. (1984) (3)
Lineage involvement and prognosis in Ph chromosome positive acute lymphoblastic leukaemia. (1998) (3)
Complex Aberrant Karyotypes and Unbalanced Translocations in CLL Correlate with an Unmutated IgVH Status: A Study on 133 Patients Studied with Chromosome Banding Analysis, Interphase FISH, IgVH Mutation Status, ZAP-70 RNA Expression and Immunophenotyping. (2005) (3)
Accumulation of Somatic Mutations As a Function of Aging: A Study on 4843 TET2 Mutated Patients in Comparison to Their Respective SNP Pattern (2015) (3)
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses (2018) (3)
Human and artificial intelligence to illuminate MDS. (2020) (3)
Integrated Diagnostic Approach for Suspected Myelodysplastic Syndrome As a Basis for Advancement of Diagnostic Criteria (2016) (3)
Machine Learning (ML) Can Successfully Support Microscopic Differential Counts of Peripheral Blood Smears in a High Throughput Hematology Laboratory (2020) (3)
Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia (2015) (3)
Analysis of Mechanisms of Blast Crisis in Chronic Myeloid Leukemia By Whole Genome Sequencing (2020) (3)
Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies (2013) (3)
The time has come for next-generation sequencing in routine diagnostic workup in hematology (2021) (3)
The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia (2016) (3)
SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3-ITD and RUNX1 Mutations (2012) (3)
Mutational Screening Of CSF3R, ASXL1, SETBP1, and SRSF2 In Chronic Neutrophilic Leukemia (CNL), Atypical CML and CMML Cases (2013) (3)
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma (2012) (3)
Artificial Intelligence Substantially Supports Chromosome Banding Analysis Maintaining Its Strengths in Hematologic Diagnostics Even in the Era of Newer Technologies (2020) (3)
Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population‐based study (2019) (3)
Gene Amplifications Are Rare Events in AML and MDS and Are Associated with Complex Karyotype, TP53 Deletions and Very Poor Survival (2011) (3)
Molecularly Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status (2014) (3)
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway (2021) (3)
Monoclonal B-Cell Lymphocytosis (MBL) Is Closely Related to Chronic Lymphocytic Leukemia (CLL) and May Be Better Classified as Early-Stage CLL. (2009) (3)
A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes (2020) (3)
Genetic Patterns of Relapsed AML Differ Significantly from First Manifestation and Are Dependent on Cytogenetic Risk Groups at Diagnosis: Results in 175 Patients with Paired Samples (2014) (3)
An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy. (2006) (3)
Trisomy 13 Defines a Subgroup of Myeloid Malignancies with an Extremely High Frequency of AML1 Gene Mutations and Newly Defined VEGFR-1 Mutations. (2006) (3)
Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials (2021) (3)
A study of TERT rare variants in myeloid neoplasia. (2022) (3)
Treatment of AML in biological subgroups (2005) (3)
Diagnostik akuter Leukämien (2012) (3)
Prognostic Impact of FLT3 Mutation Load in NPM1 Mutated AML. (2009) (3)
Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients. (2016) (3)
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML (2015) (3)
3′ Position of the FLT3-LM and Loss of Heterozygosity Are Highly Correlated to Unfavourable Outcome in AML. (2006) (3)
Cooperating Molecular Mutations in AML1/RUNX1 Mutated AML Differ Dependent on the Cytogenetic Subgroup. (2007) (3)
Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML (2021) (3)
Myelodysplastic Syndromes (MDS) With 20q Deletion Show a High Frequency Of Associated Cytogenetic and Molecular Lesions With An Association To U2AF1, SRSF2, and Prognostically Adverse ASXL1 Mutations (2013) (3)
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q (2022) (3)
Abstract 5119: Frequent splicing pathway mutations and aberrant RNA splicing in myelodysplasia (2012) (3)
ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS (2014) (3)
An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data (2019) (3)
Acute Leukemias IX (2003) (3)
Dynamic Programming for the Segmentation of Bone Marrow Cells (2015) (3)
Automated Peripheral Blood Cell Differentiation Using Artificial Intelligence - a Study with More Than 10,000 Routine Samples in a Specialized Leukemia Laboratory (2021) (3)
Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). (2009) (3)
SOX11 over-Expression Is a Specific Marker for Mantle Cell Lymphoma and Correlates with t(11;14) Translocation, CCND1 Expression, and an Adverse Prognosis. (2012) (3)
Transient response to imatinib in an atypical chronic myeloproliferative disease associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA fusion gene (2005) (3)
A Leukemic Progression Model of Severe Congenital Neutropenia Uncovers a Novel Mechanism of AML Development Involving Elevated Inflammatory Responses, Mutation of CXXC4 and Decreased TET2 Levels (2018) (2)
Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7) (2019) (2)
PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis (2019) (2)
Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases (2008) (2)
High FLT3 mRNA Expression in Acute Myeloid Leukemia May Be Functionally an Alternative to Mutational Activation of the Receptor. (2004) (2)
High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy (2012) (2)
Diagnostic Value of CD200 Expression for the Differentiation Between Chronic Lymphocytic Leukemia (CLL), CLL with Increased Prolymphocytes (CLL/PL) and Mantle Cell Lymphoma. (2012) (2)
Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets (2019) (2)
Classification of AML by DNA-oligonucleotide microarrays. (2006) (2)
Overlapping features of therapy-related and de novoNPM1-mutated AML. (2022) (2)
RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia (2011) (2)
Somatic Mutations and Inborn Variants in Exon 12 of ASXL1 in Different Myeloid Neoplasms (2011) (2)
Cytogenetic and Molecular Genetic Characterization Of MLL-PTD Positive AML In Comparison To MLL-Translocated AML (2013) (2)
The Choice of House Keeping Genes in MRD-Quantification of AML1-ETO Positive Acute Myeloid Leukemia (2004) (2)
Cord-Blood Transplantation in Patients with Minimal Residual Disease. (2016) (2)
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy (2022) (2)
Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies (2020) (2)
The CALM/AF10 Fusion: Molecular Analysis of the Fusion Transcripts in 13 Cases of AML and ALL; Gene Expression Profiling Reveals HOX Gene Deregulation. (2004) (2)
FLT3 Length Mutations and MLL-Duplications in AML: Correlation to Cytogenetics, FAB-Subtype,and Prognosis (2003) (2)
Prognosis of Mecom(EVI1)- rearranged MDS and AML Patients Strongly Depends on Accompanying Molecular Mutations but Not on Blast Counts (2015) (2)
JAK2V617F as a Cooperative Mutation in AML with Trisomy 8 and t(8;21): A Comparative Study on 271 AML and 1103 CMPD Cases. (2006) (2)
Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia (2020) (2)
C003 A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups (2007) (2)
Diagnostic value of blood gene expression-based classifiers as exemplified for acute myeloid leukemia (2018) (2)
The RUNX1 Gene Is Altered in 26% of AML Patients Either By Translocation, Mutation, Gain or Deletion (2014) (2)
Pathogenic Relevance of Germ Line TET2 Alterations (2016) (2)
IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL (2013) (2)
Impact of 9q deletions on the classification of patients with acute myeloid leukemia (2019) (2)
Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency (2013) (2)
The TP53 Codon72 Polymorphism Is Associated with TP53 Mutations in Chronic Lymphocytic Leukemia (2011) (2)
Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia (2019) (2)
Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes (2019) (2)
Flow Cytometric Determination of ZAP-70 Expression by SBZAP Antibody: Impact of Type of Data Analysis on Correlation with IgVH Mutation Status, Cytogenetics, and Level of ZAP-70 mRNA Expression in 351 Patients with Chronic Lymphocytic Leukemia (CLL). (2007) (2)
Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine (2013) (2)
160 ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE (2015) (2)
The Number of Cooperating Mutations in AML Is Still Growing: A Study on 3789 Patients. (2006) (2)
The Two Mutation Hot Spots Ser34 and Gln157 in U2AF1 Show Different Occurrence, Correlation and Clinical Features in Myeloid Malignancies: An Analysis of 785 Cases (2012) (2)
Gene Expression Profiling Identifies a Prognostically Favorable Subgroup in AML Independent of Cytogenetic Stratification. (2004) (2)
RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases (2013) (2)
Molecular landscape of immune pressure and escape in aplastic anemia (2022) (2)
Comprehensive Analysis of MYC Translocations in Multiple Myeloma By Whole Genome Sequencing and Whole Transcriptome Sequencing (2019) (2)
Cytomorphological results and dysplastic features as prognostic factors in 41 cases with acute myeloid leukemia (AML) and translocation (1994) (2)
In CML Patients with Good Response to TKIs Other Gene Mutations Are Frequently (37%) Present in Addition to Philadelphia Negative, Cytogenetically Aberrant Clones but Are Rare (4%) in Cases with MMR and Normal Karyotype (2014) (2)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (2)
Early T-Cell Precursor-ALL in Adult T-ALL. (2009) (2)
Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (2021) (2)
IDH Mutations Can Be Detected In 28.7% of All Normal Karyotype AML and Have Unfavourable Impact on the NPM1+/FLT3-ITD- Genotype (2010) (2)
Computational analysis of peripheral blood smears detects disease-associated cytomorphologies (2022) (2)
Evaluation of the New Genetic Risk Classification of the European LeukemiaNet Recommendations in 1,110 Patients with De Novo AML and Proposal of a Refined Version (2011) (2)
Role of CEBPA-Mutations in AML with Prognostically Intermediate Cytogenetics: Data of the AMLCG Study Group and Gene Expression Analyses. (2004) (2)
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML) (2013) (2)
MDS and AML With ≥15% Ring Sideroblasts Share Overlapping Features In Cytogenetics But Demonstrate Different Patterns and Incidences Of SF3B1 mutations (2013) (2)
Routinely Prepared Cells for Cytogenetic Analysis Stored at −20 °C for Several Years can be Used for RT-PCR-Based Detection of Chromosomal Aberrations in Leukemias (1998) (2)
In Depth Characterization of CLL with Normal Karyotype By Array CGH and Mutation Screening (2015) (2)
Explainable AI identifies diagnostic cells of genetic AML subtypes (2023) (2)
Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS (2022) (2)
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all demonstrating more than 50 % of bone marrow erythropoietic cells (2011) (2)
Translocations Involving the IGH@ locus Occur In 3.7% of Chronic Lymphocytic Leukemia and Are Associated with Unmutated IGHV Status and a Shorter Time to Treatment: A Study on 2,135 Cases (2010) (2)
Deep Learning Algorithms Support Distinction of PV, PMF, and ET Based on Clinical and Genetic Markers (2017) (2)
Introduction: molecular pathogenesis of hematologic malignancies. (2012) (2)
Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS (2019) (2)
Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy (2008) (2)
Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group (2011) (2)
Characterization of MDS Harboring TET2 Mutations and/or TET2 Deletions (2016) (2)
Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters (2015) (2)
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma (2021) (2)
Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis (2016) (2)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for the Genetic Characterization of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in Adults (2021) (2)
Individual Gene Expression Profiling of Bone Marrow CD34 Cells in Acquired Severe Aplastic Anemia (aSAA) in Children. (2006) (2)
Recurrent Mutations of the C-C Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) (2020) (2)
Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3‐ITD to detect patients with prognostically adverse AML (2014) (2)
Sole Trisomy 8 in AML: Concomitant Molecular Markers, Stability of Genetic Patterns and Impact On Outcome. (2012) (2)
Development of An Oligonucleotide Resequencing Array for Rapid Mutation Analysis in Acute Myeloid Leukemia with Normal Karyotype. (2009) (2)
Increased prevalence of clonal hematopoiesis of indeterminate potential in hospitalized patients with COVID-19 (2022) (2)
Detection of JAK2 Exon 12 Mutations in 10 Patients (10.1%) of V617F Negative PV: A Study of 211 Cases with PV or Suspected PV. (2007) (2)
A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next‐generation sequencing can be revealed by comparative bioinformatic analyses (2014) (2)
Bioinformatics for Medical Diagnostics: Assessment of Microarray Data in the Context of Clinical Databases (2003) (2)
Transcriptional Profiling Identifies Genes Differentially Regulated by the BCR/ABL Fusion Oncogene. (2004) (2)
Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53 (2015) (2)
Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy (2017) (2)
AML with Inv(3)(q21q26) or t(3;3)(q21;q26) Are Frequently Accompanied by Mutations in RUNX1 and NRAS and Show a High Incidence of NF1 Deletions: a Study On 40 Cases. (2009) (2)
Identification of Biologically Distinct and Clinically Relevant Subentities in Patients with Acute Myeloid Leukemia and Normal Karyotypes by Use of Gene Expression Profiling. (2004) (2)
Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors (2016) (2)
Comprehensive molecular characterization of myeloid malignancies with 9q deletion (2019) (2)
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance (2022) (2)
Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Kayotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease. (2005) (2)
Analyse prognostischer Faktoren beim Plasmozytom (1984) (2)
Immunphänotypisierung in der modernen Leukämiediagnostik (2005) (2)
Quantifizierung minimaler Resterkrankung mittels multiparametrischer Durchflusszytometrie bei der akuten myeloischen Leukämie (2005) (2)
SF3B1 Mutations in AML, MDS and MDS/MPN-RS-T Are Accompanied By Different Other Gene Mutations: Impact for Targeted Treatment Studies (2016) (1)
Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients (2019) (1)
TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients (2013) (1)
Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q (2014) (1)
Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis (2019) (1)
Acute myeloid leukemia KIT D 816 mutated / CBF-negative acute myeloid leukemia : a poor-risk subtype associated with systemic mastocytosis (2019) (1)
TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC-Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis (2013) (1)
Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias (2013) (1)
Befundinterpretation der molekularen Diagnostik in der Verlaufskontrolle der chronischen myeloischen Leukämie: Empfehlungen einer deutschen Expertengruppe/Interpretation of molecular diagnostics results in routine monitoring for chronic myeloid leukemia: recommendations from a German expert panel (2012) (1)
Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms (2015) (1)
The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q (2018) (1)
Laboratory Diagnosis of Haematological Neoplasms (2010) (1)
T-Cell Acute Lymphoblastic Leukemia Can be Subdivided into Six Genetically Distinct Subtypes with Prognostic Impact By Combination of Whole Genome and Whole Transcriptome Data (2020) (1)
Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors (2019) (1)
leukemia identifies heterogeneous secondary genomic alterations SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid (2011) (1)
Treatment of Older Patients with Acute Myeloid Leukemia (AML) (2001) (1)
Chromosome Banding Analysis Defines Subclasses of CLL with 13q14 Deletion and Identifies a New Mechanism of Submicroscopic 13q14 Deletions Occurring in the Breakpoint Region of Reciprocal Translocations. (2006) (1)
How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study (2022) (1)
Multiparameter Flow Cytometry in Patients with Suspected Myelodysplastic Syndromes Adds Significant Prognostic Information: A Study on 1,013 Patients (2011) (1)
FISH Analysis In 843 Cases with Myeloid Malignancies Revealed TET2 deletions In 6% of Patients Which Were Accompanied by TET2 Mutations In 51% of Cases (2010) (1)
Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia (2021) (1)
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 (2016) (1)
Multivariate Analysis of Prognostic Impact of Flow Cytometrically Determined Minimal Residual Disease in Patients with Acute Myeloid Leukemia. (2005) (1)
In Chronic Lymphocytic Leukemia the Gain of the Short Arm of Chromosome 2 Is Highly Associated with an Unmutated IGHV status, 11q/ATM Deletion, SF3B1 Mutation and a Complex Karyotype (2016) (1)
Sequential Evolution Versus a Single Catastrophic Event (Chromothripsis) in the Pathogenesis of AML with Complex Aberrant Karyotype (2012) (1)
MPO as a Novel Susceptibility Gene in Myeloid Malignancies (2019) (1)
Acquired Imatinib Resistance in CML Is Associated with TKD Mutations of the BCR-ABL Fusion Gene and/or Additional Chromosomal Aberrations: Certain TKD Mutations but Not TP53 Mutations Are Associated with Chromosome Instability. (2008) (1)
Gene Expression Profiling Identifies IGFBP7 as a BAALC Co-Expressed Gene with a Functional Role in Acute Leukemia. (2009) (1)
WGS and RNA-Seq Is Superior to Conventional Diagnostic Tests in Multiple Myeloma: Ready for Prime Time? (2018) (1)
mutated / CBF-negative acute myeloid leukemia (2019) (1)
European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel. (2008) (1)
Peripheral blood progenitor cell but not bone marrow grafts are affected by previous Dexa-BEAM chemotherapy (1994) (1)
Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases (2022) (1)
Comparison of TP53 Alterations in Hematological Malignancies (2015) (1)
Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts (2022) (1)
High Frequency of P53 Mutations Detected by a Microarray Resequencing Assay, the AmpliChip P53 Test, in AML with a Complex Aberrant Karyotype. (2006) (1)
Acute Myeloid Leukemia (AML): The Role of Maintenance Chemo- therapy (2004) (1)
Multiparameter Flow Cytometry Identifies Dysplasia in Granulocytic, Monocytic, and Erythrocytic Lineages and Blasts in Patients with Myelodysplastic Syndromes: Correlation with Cytomorphology and Cytogenetics. (2004) (1)
Vergleich der Stadieneinteilungen des Plasmozytoms (1986) (1)
Assessment Of Human Equilibrative Nucleoside Transporter 1 (hENT1) – Expression By Flow Cytometry In Acute Myeloid Leukemia and Myelodysplastic Syndromes and Correlation To Clinical Outcome In Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy (2013) (1)
Targeting Polo-like Kinase 4 Triggers Polyploidy and Apoptotic Cell Death in TP53-Mutant Acute Myeloid Leukemia (2021) (1)
Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features (2020) (1)
Abstract 370: T-PLL cells resemble memory-type T-cells with aberrant effector functions implicating a leukemogenic cooperation of TCL1A and TCR signaling (2017) (1)
CSF3R Mutations Are Predominantly Subclonal Events in Intermediate Risk Karyotype AML and Prevalently Occur with CEBPA Mutations (2016) (1)
A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients (2015) (1)
Methods to detect minimal residual disease (2018) (1)
A Comprehensive Deep-Sequencing Study of Blast Crisis Chronic Myeloid Leukemia (CML) Reveals New Insights Into Molecular Heterogeneity and Detects Mutations In 12 Different Genes In 82.5% of Cases (2010) (1)
Whole Genome Sequencing Identifies Single Nucleotide Variants, Structural and Copy Number Abnormalities with a High Sensitivity in Hematological Neoplasm: An All in One Diagnostic Tool Tested on 3241 Cases (2018) (1)
Near-tetraploid acute myeloid leukemias: An EGIL retrospective study of 29 cases (2005) (1)
Neue Methode zur Diagnostik von Leukämien: DNA-Microarrays (2002) (1)
Mitoxantrone, Etoposide and Prednisolone (NOVEP) in Previously Untreated Elderly Patients with Non-Hodgkin’s Lymphoma (NHL) and as Salvage Therapy for Refractory NHL (1993) (1)
The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables. (2007) (1)
Prognostic Value of “Monosomal Karyotype” in Comparison to “Complex Aberrant Karyotype” in AML: A Study on 824 Cases with Aberrant Karyotype (2011) (1)
Patients with TP53 Disruption and IGHV Mutated Status Show Indolent Clinical Course: A Study on 1,327 Treatment-Naive CLL Cases (2016) (1)
Array CGH Identifies Copy Number Changes In 10% Of 520 MDS Patients With Normal Karyotype: Deletions Encompass The Genes TET2, DNMT3A, ETV6, NF1, RUNX1, and STAG2 and Are Associated With Shorter Survival (2013) (1)
Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment (2017) (1)
An International Multi-Center Study To Define the Application of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia (MILE Study): Analysis of Completed Stage I with 2030 Patients Achieved a 95.4% Accuracy. (2007) (1)
Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) (2017) (1)
Ganglioneuroblastoma infiltrating the bone marrow in an adult (2011) (1)
Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents? (2019) (1)
Myeloid Nuclear Differentiation Antigen (MNDA) Expression: A Useful Marker in the Diagnosis of Myelodysplastic Syndromes By Flow Cytometry (2015) (1)
50 Correlation of karyotype with clinical features and prognosis in 349 patients with MDS (1997) (1)
Contents of Forthcoming Issues · Themenvorschau (2009) (1)
A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics (2013) (1)
Specific Patterns of Molecular Mutations Determine the Morphologic Differentiation Stages in Acute Myeloid Leukemia (AML) (2014) (1)
Specific subtype distribution with impact on prognosis of TP53 single hit and double hit events in AML and MDS. (2023) (1)
TET 2 Alterations in Myeloid Malignancies, Impact on Clinical Characteristics, Outcome, and Disease Predisposition (2015) (1)
Numerous Genomic Abnormalities in AML with Normal Karyotype. (2007) (1)
Correlation of Mutation Patterns with Patient Age in 2656 Cases with 11 Different Hematological Malignancies (2020) (1)
TP53 Mutations Are the Most Unfavorable Genetic Alteration in AML (2012) (1)
Excess Coincidences of Hematopoietic Neoplasms (2015) (1)
A JAK/STAT-MEDIATED INFLAMMATORY SIGNALING CASCADE DRIVES ONCOGENESIS IN AF10-REARRANGED AML. (2021) (1)
MDS and AML Are Closely Related Diseases: Gene Expression Patterns Reveal Clear Similarities with Respect to Karyotypes and Are Less Related to the Bone Marrow Blast Percentages. (2004) (1)
Microarray Classification of Myelodysplastic Syndrome (MDS) Identifies Subgroups with Distinct Clinical Outcomes. (2007) (1)
Mutations in CALR Are Associated with Del(13q) and Are Mutually Exclusive of Monosomy 7 in BCR-ABL1-Negative MPN (2014) (1)
The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases (2019) (1)
Whole Genome Sequencing in Hairy Cell Leukemia-Variant (HCL-v) and Splenic Marginal Zone Lymphoma (SMZL) (2017) (1)
Abstract 1514: Significance assessment of mutations in 944 MDS patients using publicly available variant databases and mutation impact prediction software (2016) (1)
Impact of 9q Deletions on the Classification in AML (2017) (1)
All Clinically Relevant Leukemia Subtypes Can Be Diagnosed and Classified Based Solely on Gene Expression Profiling with an Accuracy of 95.1%: A Study on 1337 Adult Patients. (2004) (1)
Comparison of Mutation Patterns Between Diagnosis and Relapse in 444 Patients with Acute Myeloid Leukemia Shows High Variability of Stability and Influence On Time to Relapse (2012) (1)
Leberbeteiligung bei hämatologischen Erkrankungen (1997) (1)
Mutational Patterns and Correlation to Chip-Related Mutations in Hematological Malignancies - a Study on Mutation Frequencies of 122 Genes in 28 Entities Including 3096 Cases (2020) (1)
Prospective Next-Generation Sequencing of Mutations in the ABL1 Kinase Domain in CML Patients Lacking Optimal Response According to ELN Guidelines (2016) (1)
Cytogenetic Aberrations In Lymphoplasmacytic Lymphoma (LPL): A Study On 166 Cases (2010) (1)
Why germline variations in ALL can matter. (2015) (1)
Myeloid Malignancies With Isochromosome 17q Harbor Frequently Mutations In ASXL1, SETBP1, and SRSF2 - This Distinct Genotype Presents With Various Morphological Phenotypes (2013) (1)
Prognostic relevance of FLT3-TED mutations in AML : the combination matters-an analysis of 3082 patients. Commentary (2008) (1)
Comparative Assessment Of Minimal Residual Disease In Acute Myeloid Leukemia By Flow Cytometry and Molecular Genetics (2013) (1)
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) (2018) (1)
Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups, (2011) (1)
Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with PM-Rara, CBFB-MYH11, and RUNX1-RUNX1T1: A Study on 600 Patients (2015) (1)
Sensitive Monitoring of Minimal Residual Disease Status in CEBPA-Mutated Acute Myeloid Leukemia Using Amplicon Deep-Sequencing (2011) (1)
High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling (2020) (1)
Employment of Machine Learning Models Yields Highly Accurate Hematological Disease Prediction from Raw Flow Cytometry Matrix Data without the Need for Visualization or Human Intervention (2020) (1)
Targeted Next-Generation Sequencing (NGS) Enables a Broad Screening of 95 Molecular Mutations In a One-Step Approach and Detects Recurrent Mutations In AML with a Normal Karyotype In MYH11 and NOTCH1 (2010) (1)
Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes (2013) (1)
Characterization of Two New Imatinib-Responsive Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Disorders. (2006) (1)
lymphoma mutations are frequent and represent an early event in follicular EZH2 (2013) (1)
The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML (2016) (1)
Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients (2010) (1)
Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1 (2012) (1)
A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia (2022) (1)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q (2021) (1)
[Immunophenotyping in modern leukemia diagnosis]. (2005) (1)
An Accumulation of Cytogenetic and Molecular Genetic Events Characterizes the Progression From MDS to Secondary AML: An Analysis of Paired Samples in 38 Patients Analyzed by Cytogenetics, Mutation Analysis and SNP Microarrays. (2009) (1)
The Interlaboratory RObustness of Next-Generation Sequencing (IRON) Study: Deep-Sequencing Investigating TET2 , CBL , and KRAS Mutations In 4464 Amplicons by An International Group Involving 8 Laboratories. (2010) (1)
In CLL with Complex Aberrant Karyotype Distinct Entities Can Be Deciphered by Molecular Genetic and Cytogenetic Parameters (2008) (1)
Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML) (2015) (1)
[Diagnosis of leukemia using microarray technology]. (2002) (1)
Comprehensive Analysis Of U2AF1 Mutations In 843 Patients With Myeloid Neoplasms With Respect To Other Genetic Alterations (2013) (1)
Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia (2022) (1)
Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia (2011) (1)
FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma - WGS Will Affect Future Treatment Decisions (2021) (1)
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]. (2006) (1)
Flow Cytometric Findings Indicative of Myelodysplasia Differ Depending on the Karyotype (2008) (1)
Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts (2013) (1)
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase (2022) (1)
A Specific Gene Expression Signature Affecting the Beta-Catenin and Notch Signaling Pathways and the Downregulation of MALAT1 Prove Acute Myeloid Leukemia with Limited Differentiation (AML-LD) as a Distinct Entity with NPM1 Mutation. (2009) (1)
P741: DDX41 MUTATIONS DEFINE A UNIQUE SUBTYPE OF MYELOID NEOPLASMS. (2022) (1)
CDKN1B Encoding the Cyclin-Dependent Kinase Inhibitor 1B (p27) but Not ETV6 Is Located in the Minimally Deleted Region of 12p Abnormalities in Myeloid Malignancies and Its Expression Is Associated with Outcome in Acute Myeloid Leukemia (AML). (2009) (1)
The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL (2012) (1)
Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations (2016) (1)
MLL-Duplications are Rare and Associated with Poor Prognosis in Acute Myeloid Leukemia (2001) (1)
Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS (2019) (1)
The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies (2014) (1)
Moderne Diagnostik bei akuten und chronischen Leukämien (2012) (1)
Up-Regulation of Heme Oxygenase-1 Is Induced by the Leukemia Stroma-Cell Interaction and Rescues Acute Myeloid Leukaemia (AML) Cells From Cytarabin Induced Cell Death (2012) (1)
Correlation of CD30 Expression on Neoplastic Mast Cells in Systemic Mastocytosis Assessed By Immunohistochemistry Versus Multiparameter Flow Cytometry and Correlation to Clinical Parameters (2015) (1)
Differentiation of promyelocytic leukemia: alterations in fas (CD95/Apo-1) and fas ligand expression (2001) (1)
Gene Amplifications In 84 Patients With Acute Myeloid Leukemia and 31 Patients With Myelodysplastic Syndrome Investigated By Array CGH (2013) (1)
A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance (2021) (1)
17p Deletion Is the Most Frequent Abnormality Acquired During Clonal Evolution in Chronic Lymphocytic Leukemia (CLL): 429 Cases Analyzed by Interphase FISH and Chromosome Banding Analysis, (2011) (1)
A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker (2014) (1)
P-027 Recurrent SETBP1 mutations in atypical chronic myeloid leukemia (2013) (1)
Although Patients with AML and Complex Aberrant Karyotype Can be Subdivided Into Different Subtypes by Cytogenetics, Prognosis is Equally Poor (2001) (1)
Flow Cytometric Identification of Biclonal Disease Among 5,523 Patients with Chronic Lymphocytic Leukemia and Its Genetic Characterization (2010) (1)
61 Clinical impact of multiparameter flow cytometry in diagnosing myelodysplastic syndromes (2011) (1)
Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders (2020) (1)
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia (2021) (1)
Deletion 7q Is Associated with KLF2 and NOTCH2 Mutations and Is Strongly Correlated with Splenic Marginal Zone Lymphoma but Also Found in Lymphoplasmacytic Lymphoma and Hairy Cell Leukemia Variant (2017) (1)
A multimodal analysis of genomic and RNA splicing features in myeloid malignancies (2023) (1)
In CLL with Normal Karyotype By Conventional and Genomic Array Karyotyping the Prognostic Impact of an Unmutated IGHV Status Is Stronger Than the Impact of Gene Mutations (2016) (1)
Rising Percentages of Blasts Are Associated with Continuously Increasing Frequencies of FLT3 -ITD and NPM1 Mutations In AML and In Addition Depend on Combinations of These Markers: Analysis of 805 Cases with Normal Karyotype AML. (2010) (1)
Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation? (1996) (1)
Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML. (2009) (1)
Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia (2021) (1)
Genomic Landscape of Acute Erythroid Leukemia (2016) (1)
A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients (2018) (1)
Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS) (2022) (1)
C009 Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics (2007) (1)
Cytogenetic and Molecular Genetic Clonal Evolution in CLL Is Associated with an Unmutated IGHV Status and Frequently Leads to a Combination of Loss of 17p and TP53 mutation (2016) (1)
Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia (2021) (1)
AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages? (2022) (1)
Intensified Therapy for AML:The Role of the HAM Combination (1998) (1)
Next-Generation Deep-Sequencing Enables a Quantitative Monitoring of RUNX1 Mutations in 534 Patients with Myelodysplastic/Myeloproliferative Neoplasms and Myelodysplastic Syndromes (2011) (1)
Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells (2022) (1)
Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia (2019) (1)
Robust and Sensitive Detection of Insertions, Deletions and Point Mutations In CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing (NGS). (2010) (1)
Whole Genome Sequencing Identifies Microdeletions Affecting TET2 and RUNX1 with Clinical Impact in Myeloid Malignancies (2021) (1)
Diagnostics of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (2016) (1)
Molecular Screening Applying a Pan-Myeloid Gene Panel Reveals Mutations in All Patients with Acute Undifferentiated Leukemia (2014) (1)
Molecular Screening In Blastic Plasmacytoid Dendritic Cell Neoplasms Reveals Mutations In TET2 and ASXL1 In The Majority Of Patients (2013) (1)
Next-Generation Sequencing (NGS) in CMML, MDS and AML Detects Molecular Mutations in Oncogenes and Allows the Identification of Balanced Chromosomal Abnormalities with Extraordinary Sensitivity and Specificity. (2009) (1)
TERT Rare Variants in Myeloid Neoplasia: Lack of Clinical Impact or Role as Risk Alleles (2021) (1)
A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques (2007) (1)
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation (2021) (1)
Landmark Analyses of DNMT3A Mutations in Hematological Malignancies (2011) (1)
Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia (2020) (1)
Answer to Comment on the Editorial ‘Should hematologists put there microscopes on eBay?’ (2015) (1)
Targeted Next-Generation Sequencing and Genome-Wide High-Resolution Copy Number DNA Arrays Allow the Identification of Five Novel RUNX1 Fusions In Hematological Malignancies. (2010) (1)
Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms (2021) (1)
Genomic subtyping and therapeutic targeting of acute erythroleukemia (2019) (1)
The Use of Unique Molecular Identifiers (UMIs) Strongly Improves Sequencing Detection Limits Allowing Earlier Detection of Small TP53 Mutated Clones in Leukemias (2016) (1)
Integration of clinical and genetic information - from patient data to gene expression analysis (2002) (1)
P735: THE ROLE OF SF3B1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES (2022) (1)
Cyclin D1 ( CCND1 ) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases (2012) (1)
Gene expression analyses in acute myeloid leukaemia (AML): current status and perspectives (2008) (1)
The Prognostic Impact of Trisomy 8 in Acute Myeloid Leukemia: Do Accompanying Aberrations Influence Prognosis? (1998) (1)
Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence (2020) (1)
Combined Impact of Aberrant Immunophenotypes, Somatic Mutations and Cytogenetic Aberrations on the Probability of Developing Myelodysplasia in Patients with Cytopenias of Undetermined Significance (2018) (1)
Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations (2015) (1)
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia (2022) (1)
'Deep insight' into microarray technology (2011) (1)
Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). (2005) (1)
RUNX1 Mutations Play a Major Role in the Progression of MDS to S-AML Following MDS: A Genetic and Cytogenetic Analysis of Sequential Samples (2008) (1)
RUNX1 Deletions Are a Novel Mechanism of Loss of Function in AML and Are Associated with Adverse Cytogenetics. (2012) (1)
Hematopathology Genomic Mechanisms of Neoplastic Diseases (2011) (0)
Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy (2022) (0)
A GENOMEWIDE ASSOCIATION STUDY IDENTIFIES NOVEL LOCI THAT PREDISPOSE TO MYELOPROLIFERATIVE NEOPLASMS (2013) (0)
In memoriam Professor Helmut Löffler (2014) (0)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) (2021) (0)
Molecular and Expression Characterization of Monosomy 7 and Del(7q) (2020) (0)
Similar Patterns of Chromosome Abnormalities in CML Occur in Addition to the Philadelphia Translocation with or without Tyrosine Kinase Inhibitor Treatment. (2009) (0)
Characterization of CMML with Normal Karyotype in Comparison to CMML with Aberrant Karyotype (2015) (0)
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (0)
Comprehensive Investigation of 225 Patients with Myeloid Malignancies and Erythroid Hyperplasia (≥50%) Demonstrates That Acute Erythroid Leukemia (AEL, according WHO Classification 2008) Differs Significantly From MDS but Overlaps with Other AML Subtypes and Pure AEL Regarding Clinical and Genetic F (2010) (0)
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial (2011) (0)
AML-156: The Clinical Implications and Outcomes of RAS Mutatome in Core-Binding Factor Acute Myeloid Leukemia (2020) (0)
Reaktive Blut- und Knochenmarkveränderungen (2020) (0)
Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/CBFB-MYH11 (2015) (0)
Untersuchungstechniken und Normalwert (2002) (0)
Chronic Myeloproliferative Disorders (2012) (0)
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies. (2023) (0)
[Gene expression analysis using DNA microarrays in soft tissue and bone tumors]. (2003) (0)
Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely (2008) (0)
A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Proﬁle: Final Results of the Valena Trial (2014) (0)
PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML (2019) (0)
Die neue WHO‐Klassifikation zur Einteilung der akuten myeloischen Leukämien (AML): Vorteile und Probleme im Vergleich zur FAB (French‐American‐British)‐Klassifikation (2002) (0)
Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis (2019) (0)
Correlation of Multiparameter Flow Cytometry and Fluorescence In Situ Hybridization in Quantifying Malignant Cells at Low Frequencies in B-Cell Lymphoproliferative Diseases. (2007) (0)
Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes (2012) (0)
CBL Mutations Are Correlated with CMML, Frequently Associated with RUNX1 but Mutually Exclusive of JAK2V617F Mutations. (2009) (0)
Akute Leuk??mien (2013) (0)
Metabolic Fatty Liver Disease (2009) (0)
Landscape of TET2 Mutations In Acute Myeloid Leukemia (AML): A Next-Generation Sequencing Study Investigating 76 Cases Comprehensively Characterized for Cytogenetics and Other Molecular Markers. (2010) (0)
Risk prediction in MDS: independent validation of the IPSS-M—ready for routine? (2023) (0)
A Comprehensive Panel of Molecular Mutations Notably Improves a Cytogenetic Prognostication System in Routine AML Diagnostics (2016) (0)
Novel Deletion Mutants in the Juxtamembrane Domain of Fms-like Tyrosine Kinase 3 (FLT3) Induce Transformation By Release from Autoinhibition in AML (2014) (0)
Analysis of Philadelphia Negative Clones Detected during Treatment with Tyrosine Kinase Inhibitors: A Study on 63 CML Cases. (2007) (0)
Cytogenetic Aberrations In Splenic Marginal Zone Lymphoma (SMZL): A Study On 134 Cases (2010) (0)
Biology Based Treatment Strategies for Acute Myeloid Leukemia (2003) (0)
Myelodysplastische/myeloproliferative Neoplasien (MDS/MPN) (Abb. 10.1, Abb. 10.2) (2010) (0)
NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring (2017) (0)
The FLT3-D324N Variant Is a Functionally Silent Polymorphism in the FLT3 Gene and May Be Associated with a Higher Risk for AML. (2004) (0)
Author Index 1993 – Autorenverzeichnis 1993 (1993) (0)
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes (2022) (0)
The Landscape of RUNX1 Mutations in Acute Myeloid Leukemia: Investigations On Stability of Mutations At Relapse and Utility As a Marker for Minimal Residual Disease (2012) (0)
Germline MPO Variants Predispose to Myeloid Neoplasia: Potential Mechanisms Suggested By In Vivo and in Vitro Studies (2021) (0)
Co-Occurrence of Separate BCR-ABL1-Positve and JAK2V617F-Positive Clones in 23 Patients Reveals Biologic and Clinical Importance (2014) (0)
Significance of Flow Cytometric and Mutational Findings in Patients with Cytopenias and Limited or No Signs of Myelodysplasia By Cytomorphology (2015) (0)
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts (2023) (0)
ZAP70 Integrates BCR-Signaling into Innate Signaling Pathways in CLL (2014) (0)
B-Cell Lymphoproliferative Disorders with t(11;14)(q13;q32) or t(14;18)(q32;q21) Can Be Subdivided into 4 Distinct Categories Based on Their Pattern of Additional Cytogenetic Aberrations and Antigen Expression. (2007) (0)
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL (2016) (0)
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study (2021) (0)
Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia (2013) (0)
Myelodysplastische/myeloproliferative Neoplasien (MDS/MPN) (2020) (0)
NPM1 Mutations Have a High Impact On the Development of Secondary AML. (2009) (0)
Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation (2011) (0)
Coincidence of JAK2V617F and BCR-ABL Is a Very Rare Event: Identification of 4 among 2317 Cases with Suspected CMPD. (2007) (0)
Therapy-Related Myeloid Neoplasms (tMN) Following Treatment of Acute Myeloid Leukemia (AML): Exome Sequencing Reveals the Presence of an Ancestral Clone Refractory to Chemotherapy (2018) (0)
Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage (2022) (0)
Assessment of CD30 expression on mast cells in systemic mastocytosis by immunohistochemistry versus multiparameter flow cytometry and correlation to clinical parameters (2016) (0)
Short communication Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia (2007) (0)
IKZF1 deletions Are Detected In 40.3% Of 270 Adult B-Precursor-ALL and Are Independently Associated With BCR-ABL1 Positivity and Inferior Outcome (2013) (0)
Detection of Minimal Residual Disease on Bone Marrow Smears by Reverse Transcriptase Polymerase Chain Reaction (1997) (0)
Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia (2022) (0)
Abstract 4259: Defining subtle cancer subtypes using the darkest DNA (2019) (0)
The Recently Suggested MDS/MPN Subgroup “Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis (RARS-T)” Demonstrates Unique Clinical, Cytogenetic, and Molecular Aspects: A Comprehensive Analysis of 57 Cases Strictly Defined According to WHO Criteria (2010) (0)
Prognostic Impact of NOTCH1 Mutations in Chronic Lymphocytic Leukemia (CLL): A Study On 538 Patients. (2012) (0)
Automatic Detection of Relevant Regions for the Morphological Analysis of Bone Marrow Slides (2016) (0)
Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics (2018) (0)
ABL populations by ultra-deep sequencing of the resistant − Unraveling the complexity of tyrosine kinase inhibitor (2013) (0)
Frequency and prognostic value of dysmyelopoiesis in 114 patients with de novo acute myeloid leukemia (AML) in an ongoing study (1994) (0)
Preview : Published ahead of advance online publication WT 1 mutations are secondary events in AML , show varying frequencies and impact on prognosis between genetic subgroups (2014) (0)
Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders (2022) (0)
Significance Assessment of Mutations in MDS Patients Using Publicly Available Databases: A Study with 944 Samples and 6 Most Significantly Mutated Genes (2015) (0)
Abstract 3176: Recurrent SETBP1 mutations in atypical chronic myeloid leukemia abrogate an ubiquitination site and dysregulate SETBP1 protein levels. (2013) (0)
Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup? (2022) (0)
Hämophagozytische Syndrome (Abb. 7.1) (2010) (0)
A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia (2022) (0)
Further Insights into the Pathogenesis of AML with Complex Aberrant Karyotype by Performing a Combination of Conventional CGH, Gene Expression and Genomic Array Analysis. (2005) (0)
Investigation Of Seven Genes Commonly Deleted In 271 Adult ALL Patients: Association With Cytogenetics and Clinical Features (2013) (0)
Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria (2020) (0)
The New WHO Classification for Akute Myeloid Leukemias and Myelodysplastic Syndromes (2003) (0)
Mathematical Modeling and Comparisons of Relapse Patterns in AML with 11q23/ MLL translocations and Normal Karyotype AML with MLL -PTD (2011) (0)
Whole Genome Sequencing in Routine Hematologic Samples: How to Proceed Analyses Best When Germline Controls Are Missing? (2018) (0)
Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation (2022) (0)
Abstract 2707: Targeted RNA sequencing reveals thus far unknown diagnostically relevant fusion partners confirming its diagnostic potential (2017) (0)
One-Mutation Model Can Explain Age Incidence in AML Carrying Nucleophosmin (NPM1) Mutations. (2007) (0)
CLL-156: Novel CCL22 Mutations Drive Chronic Lymphoproliferative Disorder of NK Cells Through Biased GPCR Signaling (2021) (0)
AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset? (2015) (0)
Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets. (2006) (0)
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AND METHYLOME IN A LARGE PATIENT COHORT (2023) (0)
Response: NPM1-mutated AML is an entity irrespective of whether or not chromosomal aberrations are present (2009) (0)
Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma. (2009) (0)
Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia (2022) (0)
Targeted RNA Sequencing Is Capable of Identifying Thus Far Unknown Partner Genes in Leukemias with Rare Translocations and Provides Important Clinical and Therapeutical Information (2016) (0)
Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability (2013) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION OF MESENCHYMAL STROMAL CELLS FROM INDIVIDUALS WITH CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) REVEALS EARLY CHANGES IN THE BONE MARROW NICHE (2023) (0)
A 19-year-old patient with atypical chronic myeloid leukemia (2020) (0)
Benigne Veränderungen der Lymphozyten (2020) (0)
Microarray Analysis Detects Unique Expression Pattern for NPM1-Mutated AML with Normal Karyotype and Reveals Pathobiological Insights. (2007) (0)
Dissecting the Knowns for the Unknowns: Refining the Classification of Genomic Variations in Hematological Diseases By the Clingen Hematological Cancer Taskforce (HCT) (2022) (0)
About 17% of AML with NPM1 mutations Show a Specific Pattern of Chromosome Aberrations but These Cases Do Not Differ Prognostically from AML with NPM1 Mutations Carrying a Normal Karyotype (2008) (0)
DNA Methylation and Genetic Profiles in 320 Patients with Myelodysplastic Syndromes (2018) (0)
Comprehensive Cytogenetic and Molecular Genetic Characterization of T-PLL Identifies for the First Time BCOR Mutations in a Lymphatic Disease. (2012) (0)
Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia (2016) (0)
and survival of APL cells PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation (2013) (0)
Invariant Patterns of Clonal Succession Determines Specific Phenotypic and Clinical Features of Myelodysplastic Syndromes (MDS) (2018) (0)
Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards (2016) (0)
Acute Myeloid Leukemia with Translocation t(8;16) Demonstrates Specific Cytomorphological, Cytogenetic, and Gene Expression Characteristics and Can Clearly Be Discriminated from Other AML with Balanced Translocations. (2004) (0)
Impact of FLT3 Mutation Status and Other Genetic Parameters In Acute Promyelocytic Leukemia (APL) with t(15;17)(q22;q12)/PML-RARA. (2010) (0)
Serial Assessment of Patients with Suspected Myelodysplastic Syndromes: Significance of Flow Cytometric Findings As Validated by Cytomorphology, Cytogenetics, and Molecular Genetics (2011) (0)
Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations (2022) (0)
Abstract 4602: Recurrent pathway mutations of multiple components of cohesin complex in myeloid neoplasms. (2013) (0)
Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications (2019) (0)
Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment (2022) (0)
The Prognostic Impact of High EVI1 expression In AML Is Due to Its Close Correlation to Rearrangements Involving EVI1 or MLL, which Are Cytogenetically Cryptic In a Subset of Patients : a Study on 332 Cases. (2010) (0)
CONSENSUS DOCUMENT ICON : Eosinophil Disorders (0)
Title Pages / Table of Contents (2012) (0)
FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy (2018) (0)
Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity (2011) (0)
Acute Lymphoblastic Leukemia (ALL) with Low-Hypodiploid/near Triploid Karyotype Is a Specific Clinical Entity with Poor Outcome (2012) (0)
The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia (2019) (0)
Progress in the molecular diagnostics of hematologic neoplasia. (2020) (0)
[Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis]. (2005) (0)
Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes (2022) (0)
Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia (2022) (0)
Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia (2019) (0)
Deletion of the Tumor Suppressor Gene NF1 Is An Alternative Mechanism for Aberrant Activation of the RAS Pathway and Is Found in 11% of Acute Myeloid Leukemia. (2009) (0)
Molecular Genetics of MDS: TH‐S17‐EB‐010 (2018) (0)
Neues aus der Hämatologischen Diagnostik1) (2014) (0)
High-Throughput Sequencing to Identify Cytogenetic and Molecular Genetic Aberrations in 24 AML Exomes (2014) (0)
Literatur zu Kapitel 6.7: Microarray-Analysen (2008) (0)
Branchiogene Zysten und bronchoalveoläre Lavage (2002) (0)
Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms (2022) (0)
Lineage involvement and prognosis in Ph chromosome positive acute lymphoblastic leukaemia: a reply (1998) (0)
DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity (2018) (0)
[Diagnostics and therapy of acute myeloid leukemia]. (2002) (0)
The Karyotype in MDS — Cytogenetic Profile, Clinical Correlations and Prognostic Implications in 362 Patients with MDS (1998) (0)
A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease (2017) (0)
ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia (2021) (0)
Angeborene Anomalien der Granulozytopoese (2020) (0)
Precision Medicine in Therapy of Non-solid Cancer. (2022) (0)
Correlation Between Cytogenetic Aberrations Detected by Conventional Chromosome Banding Analysis and Specific Immunophenotypes in Patients with B-Cell Lymphoproliferative Diseases (2008) (0)
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes (2022) (0)
Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS (2019) (0)
Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools (2022) (0)
A Completely Digital Workflow for Differentials in Bone Marrow Cytomorphology Supported By Machine Learning Provides Promising Results in Object Detection (2021) (0)
Myelodysplastic Syndromes and Philadelphia Negative Chronic Myeloproliferative Diseases Show an Overlapping Pattern of Cytogenetic Aberrations. (2007) (0)
LYMPHOID NEOPLASIA Integration of innate into adaptive immune responses in ZAP-70 – positive chronic lymphocytic leukemia (2016) (0)
Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken. (2019) (0)
The Use of NGS for Molecular Investigations in Leukemia Adds Important Biological, Clinical and Prognostic Information Due to Its Higher Sensitivity in Comparison to the Gold Standard Sanger Sequencing (2016) (0)
Identification of Epigenetically Silenced Tumor Suppressor Genes in Myeloid Disorders Leads to the Identification of α-Catenin as a Target Gene in 5q- Syndrome. (2004) (0)
Identification of Specific Genes Expression Signatures for CEBPa, NPM1 and FLT3 Genes Mutations in AML. A Study Based of the MILE Data Issued from 79 French Samples. (2007) (0)
Hämophagozytische Syndrome (2020) (0)
S119: CEBPA AND TET2 MUTATIONS COOPERATE TO INDUCE AGGRESSIVE AML VIA GATA-2 DOWNREGULATION (2022) (0)
Unusual Course of Myelodysplastic Syndrome with Presumed Familial Origin (2011) (0)
Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study (2010) (0)
Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia (2022) (0)
Proposal for an efficient schedule for genetic diagnostics in chronic myeloid leukemia (2000) (0)
Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach (2003) (0)
Overexpression of the Metabolic Stress Sensor and Proglycolytic Transcription Factor ΜLΧΙΡ Mediates Malignancy of Common Acute Lymphoblastic Leukemia in Vivo and Is Targetable By Allorestricted Peptide Specific T Cells (2014) (0)
Use Of Flow Cytometry To Identify Myelodysplasia In Peripheral Blood (2013) (0)
Prognosis In Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Count but Depends on Cytogenetic and Molecular Genetic Parameters (2010) (0)
Aplastische Anämien (Panmyelopathien) (2020) (0)
Different Mechanisms Lead to Rearrangements of the MLL Gene in Cases with Acute Myeloid Leukemia (AML) and Translocation t(10;l1) (2003) (0)
14q Deletions Are Recurrent Aberrations in CLL and Other Mature B-Cell Neoplasms and Show a High Coincidence with An Unmutated IgVH Status and Trisomy 12, and Are Associated with An Intermediate Overall Survival and a Shorter Time to Treatment. (2009) (0)
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]. (2007) (0)
WT1 Expression as Follow up Marker in CML: Low Impact and Sensitivity Compared to BCR-ABL Specific RQ-PCR but High Impact for Detection of New Aberrant Clones in BCR-ABL Negative Follow up Samples (2008) (0)
Methylation of the Proximal, Distal and Core Promoter of CEBPA in 574 Cases with Normal Karyotype AML and 44 with t(8;21) Disclosed Different Frequencies but No Impact on Prognosis (2011) (0)
Identification and Characterization of Potential Candidates for Treatment Targeting Apoptosis Pathways in Patients with Hematological Neoplasms (2018) (0)
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain (2013) (0)
In Myelodysplastic/Myeloproliferative Neoplasms Aberrant Antigen Expression As Assessed by Multiparameter Flow Cytometry Is Related to Molecular Genetic Mutations (2011) (0)
Deep-Sequencing Of The Molecular Landscape In Burkitt Lymphoma/Leukemia (2013) (0)
Chronische myeloische Leukämie und andere chronische myeloproliferative Erkrankungen (2003) (0)
Complex Aberrant Karyotypes Are Associated with Dismal Prognosis in CLL: Chromosome Banding Analysis Provides Important Prognostic Information in CLL in Addition to Interphase-FISH (2008) (0)
High Density SNP Array Analysis of Tyrosine Kinase Inhibitor (TKI) Resistant Chronic Myeloid Leukemia (CML) Shows Secondary Genomic Alterations (2008) (0)
Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis (2013) (0)
S886 CLASSIFICATION OF MYELOPROLIFERATIVE NEOPLASMS BASED ON DEEP LEARNING ALGORITHMS AND MOLECULAR GENETIC MARKERS SUPPORT DISTINCTION OF CML, PV, ET, AND PMF (2019) (0)
Myeloproliferative Neoplasien (MPN) (2013) (0)
Acute Myeloid Leukemia With t(8;21)/RUNX1-RUNX1T1 demonstrate a High Number Of Secondary Genetic Lesions: Frequency and Impact On Clinical Outcome (2013) (0)
Application of Multiparameter Flow Cytometry for the Identification of Dysplasia in Granulocytic, Monocytic, and Erythrocytic Lineages and Blasts in Patients with Myelodysplastic Syndromes. (2006) (0)
The Investigation of Molecular Markers in the Prognostically Intermediate Karyotype Group in AML Provides Clinically Relevant Information. (2004) (0)
Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms (2016) (0)
Contents Vol. 126, 2011 (2011) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION (2023) (0)
Different mechanisms can lead to MLL-rearrangements in cases with t (2001) (0)
Abstract LB-329: Enhancing the resolution and accelerating the pace of translational fusion characterization in oncology by RNA sequencing (2016) (0)
Angeborene Anomalien der Granulozytopoese (Abb. 3.1) (2010) (0)
Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns (2015) (0)
Myelodysplastic Syndromes: A More Global 5-Hydroxymethylcytosine Deficiency Disorder Than Suggested By the Presence of TET2 Mutations (2021) (0)
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database (2022) (0)
Diagnostics of MPNs – to be or not to be? (2016) (0)
Mutant TP53 prevents Telomere Shortening in Acute Myeloid Leukemia (2021) (0)
Myeloische Neoplasien mit Keimbahn-Prädisposition (2020) (0)
Targeting Genomic Heterogeneity of Adult Acute Lymphoblastic Leukemia (2014) (0)
Abstract 2993: Patterns of recurrent mutations in SETBP1 mutated and wild-type atypical Chronic Myeloid Leukemia patients. (2013) (0)
Analysis of the V617F Mutation of the JAK2- and the W515 Mutation of the MPL Gene in Patients with Chronic Myeloproliferative Disease (CMPD) Treated in an Outpatient Practice. (2007) (0)
Using Whole Genome Sequencing (WGS) of 3256 Patients with Hematologic Malignancies to Determine Genome Instability (2018) (0)
Expression of cytokine receptors on AML blasts (2001) (0)
Die Leukämiediagnostik steht vor einem großen Umbruch (2018) (0)
Phenotype/Genotype Associations in TET2-Driven Myeloid Neoplasms (2016) (0)
Molecular Landscape of MDS (2020) (0)
Analysis of 12 Genes in 268 Cases with CMML Identifies ASXL1 Mutations As the Most Important Genetic Alteration Associated with Adverse Outcome (2012) (0)
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis (2015) (0)
Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression (2022) (0)
Gene Expression Profiling in Adult Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, and Acute Myeloid Leukemia M0: Confirmation of Immunophenotypic and Cytogenetic Diagnostic Findings. (2004) (0)
Novel Synthetic Lethal Targets for Myeloid Neoplasms with Loss of Chromosome 7 (2021) (0)
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms (2020) (0)
In BCR-ABL1 Negative Myeloproliferative Neoplasms the Detection of JAK2exon12, MPLW515, CBL, KITD816V, FIP1L1-PDGFRA Mutations Are Closely Linked to Specific Entities, Whereas the JAK2V617F, TET2, or EZH2 Mutations Demonstrate a Broader Diversity: Patterns From Diagnostic Reports of 18,547 Patients (2010) (0)
Hsp70-peptide activated autologous NK cells in the immunotherpay of cancer — a clinical pilot study (2001) (0)
Time Points, Dynamics and Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with NPM1 mutation: A Study on 428 Patients (2016) (0)
How do I Diagnose MDS Using Currently Available Tools (2017) (0)
O-005 Mutations in U2AF1 highly associate with MDS-RAEB and del(20q) (2013) (0)
Optimization of the indications for allogeneic stem cell transplantation in Acute Myeloid Leukemia based on interactive diagnostic strategies (2008) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling (2021) (0)
Next Generation Sequencing: Should it Become Part of Routine Diagnostics for Leukemias and Other Myeloid Neoplasms? (2012) (0)
RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression (2022) (0)
Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders. (2008) (0)
PPM1D Mutations in MDS Patients with Deletion of Chromosome 5q (2017) (0)
Gene Expression Profiling Demonstrates Similar Biological Patterns in t-AML vs. de novo AML: A Study Including 106 Patients. (2004) (0)
A Study on Paired Tissue Sequencing in Hematologic Diseases to Distinguish Somatic from Germline Sequence Variants in Routine Diagnostics (2016) (0)
INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2019) (0)
Correction: complex landscape of alternative splicing in myeloid neoplasms (2021) (0)
TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial (2013) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution (2021) (0)
EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/PICALM-MLLT10 Positive Acute Leukemias, (2011) (0)
Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing (2022) (0)
The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients (2018) (0)
Comprehensive Molecular Analyses of BCR-ABL1 Negative MPN Show That PMF Is Genetically Much More Heterogeneous Than ET and PV (2014) (0)
Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients (2021) (0)
Inhalt, Vol. 16, 1993 (1993) (0)
Automated Disease Classification Using Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data with Transparent Artificial Intelligence (AI) (2021) (0)
AML classification in the year 2023: How to avoid a Babylonian confusion of languages. (2023) (0)
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia (2023) (0)
Molecular Analysis of RAS-RAF Tyrosine-Kinase Signaling Pathway Alterations in Multiple Myeloma (2011) (0)
the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes (2016) (0)
Occurrence of T-Lymphocytes with Aberrant Immunophenotypes Suggestive of Mature T-Cell Neoplasms In Patients with Hairy Cell Leukemia (2010) (0)
Chromosome Banding Analysis Allows a More Precise Classification of CLL Than Interphase FISH: A Study on 446 Cases. (2006) (0)
Incidential Findings of Mutations in the PIGA Gene Are Highly Specific for the Presence of PNH Clones (2021) (0)
Challenging gold standard hematology diagnostics through the introduction of whole genome sequencing and artificial intelligence (2023) (0)
Acute myeloid leukemia (2019) (0)
Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression (2018) (0)
Contents, Vol. 16, 1993 (1983) (0)
Characterization of Del(14)(q24q32) in Mature B-Cell Neoplasms By Array-CGH, Cytogenetics and Molecular Mutations (2015) (0)
Cytogenetic and Molecular Genetic Shifts in 27 Genes Investigated By NGS Depict Specific Routes from MDS to s-AML in 38 Patients with Paired Samples (2014) (0)
Role of Screening for Molecular Mutations in Patients with Suspected MDS (2017) (0)
An International Multi-Center Microarray Study for the Molecular Classification of Leukemia Identifies Novel Sub-Groupings in MDS Overlapping with AML. (2006) (0)
Putative Germline Variants in the Predisposition Genes DDX41, ETV6 and GATA2 investigated in 1,228 Patients with Sporadic AML or MDS (2020) (0)
Cracking a Nut with a Sledgehammer? - Broadening the Spectrum of Gene Mutation Analysis in MDS Does Not Add Clinically Relevant Information (2020) (0)
TP53 Mutations, Deletions, and CN-LOH: Comparison of TP53 single Hit and Double Hit Events and Their Impact on Prognosis in Hematological Malignancies (2021) (0)
Copy-Neutral Loss-of-Heterozygosity Adds Diagnostic and Prognostic Information to the Molecular Profiling of Hematological Malignancies (2021) (0)
MDS subclassification—do we still have to count blasts? (2022) (0)
A MAFB Associated Regulatory Network Distinguishes CMML from Other MDS/MPN Overlap Entities (2018) (0)
Flow Cytometric Assessment of Myeloid Nuclear Differentiation Antigen (MNDA) Expression in Myelodysplastic Syndromes As a Diagnostic Marker (2011) (0)
Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies (2022) (0)
Mast cell leukemia: clinical heterogeneity, molecular aberrations and prognostic factors (2016) (0)
The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA (2022) (0)
Overexpression of BAALC Indicates Drug Resistance and Inferior Survival in Adult B-Precursor Acute Lymphoblastic Leukemia. (2009) (0)
Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS) (2022) (0)
Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study. (2004) (0)
Translocation t(14;19)(q32;q13) Is a Rare Abnormality in CLL and Associated with Trisomy 12, an Unmutated IgVH Status and a Distinct Gene Expression Profile. (2007) (0)
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study (2018) (0)
Development of Molecular Mutations during the Evolution of Therapy-Related MDS and Therapy-Related AML (2014) (0)
DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED (2013) (0)
Identification and Characterization of Three Novel Cytogenetically Cryptic EVI1 Rearrangements Identified in 27 AML Patients All Predicting An Unfavorable Outcome (2011) (0)
Comprehensive Analysis of Mixed Phenotype Acute Leukemia (MPAL) By Whole Genome Sequencing (2017) (0)
O-006 SF3B1 mutations in MDS subgroups and s-AML and their association with cytogenetics and other molecular markers (2013) (0)
Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias (2013) (0)
Prognostic Impact of Multiparameter Flow Cytometry in Patients Analyzed for Suspected MDS. (2012) (0)
JAK2 Mutation Screening and Chromosome Analysis Are Necessary for a Comprehensive Diagnostic Work up in CMPD: A Study on 469 Cases. (2005) (0)
Überwiegen polynukleärer (segmentierter) Zellen (2002) (0)
Endodermaler Sinustumor (Dottersacktumor) des vorderen Mediastinums (1990) (0)
Zellzusammensetzung des Knochenmarks und Prinzipien der Auswertung (2002) (0)
Buchbesprechung · Book Review (1998) (0)
Die einzelnen Zellelemente der Hämatopoese (2002) (0)
Thrombozytensammlung mit dem A3p-Programm beim Blutzellseparator Haemonetics MCS3p (1996) (0)
Therapie der chronischen myeloischen Leukämie bei älteren Patienten (2010) (0)
Neue Erkenntnisse in der Diagnostik chronischer myeloproliferativer Syndrome (2007) (0)
Polycythaemia vera und sekundäre Erythrozytosen (Polyglobulie) (2002) (0)
Tumoraspirate bei Knochenmarkbefall (Abb. 15.1–15.7) (2010) (0)
Vorbemerkungen zur Physiologie und Pathophysiologie der Blutzellsysteme (2002) (0)
Tumoraspirate bei Knochenmarkbefall (2020) (0)
Lymphatische Neoplasien (2020) (0)
Myelodysplastische Syndrome (MDS) (2020) (0)
Diagnostik von myelodysplastischen Syndromen (MDS) und akuten myeloischen Leukämien (AML) (2015) (0)
Blutparasiten und andere, wichtige Erreger von Tropenkrankheiten (2004) (0)
Molekulare Klassifikation von Leukämien durch Einsatz von Genexpressionsanalysen (2004) (0)
Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukamien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation/The New WHO Classification for Acute Myeloid Leukemias: Comparison to the FAB Classification (2002) (0)
Störungen der Erythropoese (2020) (0)
Pattern of Chromosomal Aberrations and IgVH Mutation Status in Patients with Monoclonal B-Cell Lymphocytosis (MBL) (2008) (0)
Microarray analysis and expression profiling (2004) (0)
IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup (2022) (0)
Membrane expression of heat shock protein 70 (Hsp70) in hematological malignancies (2001) (0)
Immunostimulatory CpG-Oligonucleotide Activated Metaphase Cytogenetics Is Feasible in Routine Diagnostics of Chronic Lymphocytic Leukaemia and Reveals More Abnormalities Than Interphase FISH. (2005) (0)
Help for Ukrainian Hematology Patients (HUP): A Global Initiative Supporting Hematopoietic Stem Cell Transplantation (HSCT) Programs in a Time of Conflict (2023) (0)
Microarrays Are a Robust Platform Suitable for Diagnostics. (2004) (0)
I-001 Advanced course (2013) (0)
Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach (2013) (0)
CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q) (2019) (0)
Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1, CEBPA, RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome (2015) (0)
NRAS Mutations in AML: Biology, Cytogenetics, and Prognostic Impact in 2502 Patients. (2005) (0)
Whole Genome Sequencing Identifies Non-KIT Mutations and Cytogenetic Aberrations in Systemic Mastocytosis but Has Limited Sensitivity for Detection of KIT D816V (2021) (0)
Primary and Secondary Hematological Neoplasms - Are They Related? (2019) (0)
A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis (2022) (0)
Myeloische und lymphatische Neoplasien mit Eosinophilie und Anomalien von PDGFRA, PDGFRB oder FGFR1 (2013) (0)
Intraplatform Reproducibility and Technical Precision of Gene Expression Profiling in Four Laboratories Investigating 112 Leukemia Samples: The DACH Study. (2007) (0)
Comprehensive Genetic Analyses Of 213 PMF Patients Revealed 13% Of SRSF2 Mutations Being Strongly Correlated To ASXL1 Mutations (2013) (0)
exon 12 mutations JAK2 associated with Molecular and clinical features of the myeloproliferative neoplasm (2013) (0)
A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients (2020) (0)
Analysis of the Genetic Background in Patients with Myeloid Malignancies and Divergent Findings Regarding Blasts As Determined By Cytomorphology and Flow Cytometry (2019) (0)
Degree of Aberrant Antigen Expression in Myelodysplastic Syndromes Correlates with the Number of Molecular Mutations (2015) (0)
Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course, (2011) (0)
MicroRNA expression profiling in Acute myeloid leukemia patients (2009) (0)
Störungen der Thrombozyten (2002) (0)
FIP1L1-PDGFRA Positive Secondary Acute Myeloid Leukemia. (2005) (0)
Ultra-Deep Sequencing Leads to Earlier and More Sensitive Detection of the TKI Resistance Mutation p.T315I in CML (2014) (0)
ETV6 Rearrangements Are Recurrent Genetic Events In Myeloid Malignancies and In AML Are Associated with NPM1- and RUNX1-Mutations and An Intermediate Prognosis (2010) (0)
Weiterführende und verwendete Literatur (2002) (0)
ERG Overexpression Is Highly Associated With ERG Gene Amplifications In Patients With Myeloid Malignancies (2013) (0)
Aplastische Anämien (Panmyelopathien, Abb. 5.1) (2013) (0)
Mutations in the AML1 Gene Define an Unfavorable Subgroup in Acute Myeloid Leukemia with FAB M0. (2004) (0)
Analysis For Loss Of 13q Heterozygosity Using STR Or SNP Analysis Can Replace Analysis Of FLT3-ITD To Detect Prognostically Adverse AML (2013) (0)
Diagnostik von leukämischen Erkrankungen (2022) (0)
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database (2021) (0)
Klassifikation von Leukämien (2008) (0)
A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM) (2014) (0)
219 RELATION BETWEEN MOLECULAR MUTATIONS AND ABERRANTLY EXPRESSED ANTIGENS IN MYELODYSPLASTIC SYNDROMES (2015) (0)
P-053 Characterization of 305 patients with myelodysplastic syndromes and 20q-deletion: Cytomorphological features, and concomitant cytogenetic and molecular genetic alterations (2013) (0)
Complete or Partial Deletions of IKZF1 Occur In 28% of Blast Crisis CML and Are the Only Recurrent Submicroscopic Alteration Associated with Disease Progression: An Analysis of 43 Cases Using High-Resolution Genome-Wide Copy Number DNA Arrays and Molecular Assays (2010) (0)
Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries (2019) (0)
Interphase FISH and Comparative Genomic Hybridization Performed in Addition to Chromosome Banding Analysis in AML with Normal Karyotype Detect Prognostically Relevant Chromosome Abnormalities. (2004) (0)
Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting (2022) (0)
Homozygosity of Mutated Calreticulin in Myeloproliferative Neoplasms By an Acquired Chromosome 19p UPD Is Associated with Deletions in the Long Arm of Chromosome 5 and SF3B1 Mutations (2016) (0)
Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes (2018) (0)
Impact of 1p Deletions in Myelodysplastic Syndromes and Secondary AML Arising from Myelodysplastic Syndromes (2016) (0)
Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity? (2015) (0)
6.7 Microarray-Analysen (2008) (0)
[A comparison of staging classifications of plasmacytoma]. (1986) (0)
Analyzing the Transcriptome Discovers up-Regulation of HOXA Genes in Patients with Myeloid Neoplasms and Isochromosome 17q and Mutations in ASXL1, SETBP1 and SRSF2 (2016) (0)
Flow Cytometric Assessment of the T-Cell Receptor Vβ Repertoire Identifies Clonal T-Cell Populations with High Specificity and Sensitivity. (2012) (0)
Distinct Features of Chip-Derived and De Novo MDS (2018) (0)
Analysis with the LightCycler System® Identifies a Highly Significant Correlation between ZAP-70 mRNA Expression and Immunoglobulin Variable Heavy Chain Gene Mutational Status in Chronic Lymphocytic Leukemia. (2005) (0)
Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes (2015) (0)
MDS-097: Consequences of the Clonal Hierarchy of SF3B1 Mutations on Clinical Phenotypes and Outcomes in Myeloid Neoplasia (2020) (0)
alpha-resistant patients with hairy cell leukemia Effective natural interferon-alpha therapy in recombinant interferon- (2011) (0)
Circulating microbial content in myeloid malignancy patients carries diagnostic and prognostic potential (2021) (0)
Klinische Forschung im „European LeukemiaNet” (2006) (0)
Molecular diagnostics and risk assessment in myeloid malignancies (2019) (0)
Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke (2023) (0)
PCR-Based MRD Detection in AML with Normal Karyotype or Other intermediate Risk Aberrations by the Use of FLT3-LM, NPM1-Mutations, MLL-PTD or WT1-Overexpression. (2006) (0)
Comprehensive Molecular Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Mutations in 76 (97.4%) of 78 Patients (2011) (0)
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL (2018) (0)
Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome (2015) (0)
AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria. (2008) (0)
RUNX1 Mutated AML Are Associated with a Distinct Pattern of Cytogenetic and Additional Molecular Genetic Abnormalities (2014) (0)
Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial (2014) (0)
CONVERGENCE OF GENOMICS AND TRANSCRIPTOMIC PATTERNS IN MDS (2023) (0)
Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype (2018) (0)
Genomic landscape in KIT D816V+ advanced systemic mastocytosis (2015) (0)
Abstract 5788: Genomic and transcriptomic profiles of DNA damage response genes in acute myeloid leukemia (2022) (0)
Myelodysplastic syndromes, second edition (2013) (0)
Abstract 4248: A long tail of sub-clonal TP53 mutations emerged by ultra-deep sequencing of newly diagnosed multiple myeloma (MM) (2015) (0)
KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML) (2018) (0)
Short communication Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia (2010) (0)
An Approach to Virtual Karyotyping for Unbalanced Rearrangements Based on Gene Expression Data. (2007) (0)
Biologic Determinants for AML Therapy (1998) (0)
Short communication Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases (2007) (0)
The Incidence of TP53 Mutations Is Low in Leukemia Overall but High in the Subgroups with Complex Aberrant Karyotypes: A Study on 309 Cases. (2006) (0)
Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing (2022) (0)
Older-age AML: Disease biology and dose response (2007) (0)
Abstract 3275: Comparison of somatic variant interpretation results between human experts and automated classification using AMP/ASCO/CAP guidelines (2018) (0)
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders (2021) (0)
Quantification of Minimal Residual Disease (MRD) in MLL-PTD Positive AML Can Be Used for Prognostication in AML with Normal Karyotype. (2004) (0)
Dokumentation und Evaluation der Weiterbildung Contents of Forthcoming Issues · Themenvorschau (2016) (0)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL (2022) (0)
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis (2022) (0)
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis (2022) (0)
Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022 (2022) (0)
Therapeutic and Prognostic Factors in the Management of Acute Myeloid Leukemia (1997) (0)
Ultra-Deep Next-Generation Sequencing (NGS) Detects BCR-ABL1 Kinase Domain Mutations with High Sensitivity and Allows to Monitor the Composition of Distinct Subclones During Tyrosine Kinase Inhibitor Treatment (2010) (0)
A NUP98-NSD1 Fusion Gene Can Be Detected in a Small Subset of Adult AML Patients with Normal Karyotype (2011) (0)
TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression. (2009) (0)
Histiozytäre Neoplasien und Neoplasien der dendritischen Zellen (2020) (0)
Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles (2020) (0)
Acute myeloid leukemia displaying clonal instability during treatment: implications for measurable residual disease assessments. (2022) (0)
The Type of Genetic Abnormalities Causing Loss of 5q Varies Between MDS and AML and Is Associated with Worse Prognosis in MDS (2012) (0)
Towards a Comprehensive Prognostic Score in CLL Based On a Combination of Genetic Parameters. (2009) (0)
Gene Expression Profiling by Microarrays: Gene expression profiling for the diagnosis of acute leukemias (2006) (0)
Automated Comprehensive Diagnostics of Hematologic Neoplasms By Artificial Intelligence Models Using Flow Cytometric Raw Matrix Data (2021) (0)
Impact of Trisomy 8 on Expression of Genes Located on Chromosome 8 in Different AML Subgroups. (2004) (0)
Gene Expression Profiling to Detect New Treatment Targets in Leukemia and Lymphoma: A Future Perspective (2019) (0)
Myeloproliferative Neoplasien (MPN) und Mastzellerkrankungen (2020) (0)
Clinical Relevance of Concomitant Gene Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia. (2012) (0)
Klinisch relevantes Einteilungsprinzip der Anämien nach dem Hb-Gehalt des einzelnen Erythrozyten (MCH) (2002) (0)
Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact (2019) (0)
Biological and genetic characterization of the role of SRSF2 mutations in the pathogenesis of myelodysplastic syndromes (2015) (0)
A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI (2022) (0)
Impact of Expression of BAALC , CDKN1B, ERG , EVI1 , and MN1 on Prognosis and Their Association with Karyotype, FLT3 -ITD, NPM1 and MLL -PTD Status In Adult AML: A Comprehensive Study on 286 Cases (2010) (0)
Autologous or allogeneic stem cell transplantation versus chemotherapy in acute myeloid leukemia and subgroups: A multicenter trial by the German AML Cooperative Group. (2006) (0)
Non-Random Interactions between Founder and Subclonal Mutations Shape the Clinical and Morphological Features of MDS (2017) (0)
P744: UNBALANCED TRANSLOCATION DER(1;7)(Q10;P10) AS A DISTINCT SUBTYPE IN MYELODYSPLASTIC SYNDROMES (2022) (0)
Detection of Dysplastic Features by Multiparameter Flow Cytometry in Myelodysplastic Syndromes in Relation to Cytomorphology and Cytogenetics. (2007) (0)
How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing (2022) (0)
Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML) (2012) (0)
Abstract: A Database and Neural Network for Highly Accurate Classification of Single Bone Marrow Cells (2022) (0)
Characterization and Prognostic Impact of Multiple Productive IGHV Rearrangements in CLL (2016) (0)
Mild hyperphenylalaninemia (2020) (0)
The Detection of Multilineage Dysplasia (MLD) Has No Influence on Prognosis in NPM1 Mutated Acute Myeloid Leukemia (AML) with Normal Karyotype (2008) (0)
MYC Translocations In Mature B-Cell Neoplasms: Single, Double, Triple and Quadruple Hit Lymphoma (2013) (0)
Use of 5-Fold Staining for Multiparameter Flow Cytometry-Based Quantification of Minimal Residual Disease in Acute Myeloid Leukemia Results in Improved Sensitivity. (2004) (0)
Flow Cytometric Characterization of Genetically Defined Subgroups of Chronic Lymphocytic Leukemia: Basis for the Comprehensive Definition of Prognostic Parameters. (2004) (0)
PS922 BENEFITS OF RNA SEQUENCING IN DETECTING RECURRENT AND NOVEL FUSION TRANSCRIPTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (2019) (0)
Evaluation of BRAF V600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma. (2012) (0)
Loss or Mutation of TP53 Is Highly Associated with Complex Aberrant Karyotype and Chromosomal Translocations in Chronic Lymphocytic Leukemia. (2006) (0)
TP53 Mutations in Acute Myeloid Leukemia (2015) (0)
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium (2015) (0)
Frequency and Prognostic Impact of CD8 Expression In 5,523 Patients with Chronic Lymphocytic Leukemia (CLL) In Relation to Chromosomal Aberrations, IGHV Mutational Status and ZAP-70 Expression. (2010) (0)
Specific Molecular Mutations with Prognostic Relevance in AML with Normal Karyotype Are Also Associated with Outcome in AML with Aberrant Karyotype: A Study on 1981 Cases, (2011) (0)
Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies (2022) (0)
The Role of NRAS G12D Mutations in the Response to Conventional Chemotherapy and 5-Azacitidine in Secondary AML (2018) (0)
CML Patients with Philadelphia-Negative Clones Occurring During Treatment with Tyrosine Kinase Inhibitors Harbor Molecular Mutations Typical for MDS. (2012) (0)
Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms (2018) (0)
Molecular dissection of normal karyotype acute myeloid leukemia. (2020) (0)
Whole Genome Sequencing and RNA Sequencing of 27 Patients with Persistent Polyclonal B-Cell Lymphocytosis Reveals a High Mutation Frequency/Overexpression of Lymphoma Associated Genes: Really a Benign Disorder? (2018) (0)
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics (2023) (0)
Empfehlungen zur Verlaufskontrolle und Zweitlinientherapie bei der chronischen myeloischen Leukämie (CML) (2010) (0)
A Distinct Pattern of Additional Aberrations and Novel Mechanisms of MLLRearrangements Are Detectable in AML with 11q23 Aberrations Using SNP Arrays (2008) (0)
[Liver involvement in hematologic diseases]. (1997) (0)
Clinical Phenotype of Myeloproliferative Neoplasms with Activating CBL-mutations Resembles Chronic Myelomonocytic Leukemia. (2009) (0)
WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis (2013) (0)
Molecular Characterization of B-Cell Neoplasms Harboring MYC Translocations (2013) (0)
Clinical characteristics and treatment with ruxolitinib in patients with PCM1-JAK2 and BCR-JAK2 positive myeloid/lymphoid neoplasms with eosinophilia (2017) (0)
Development and validation of a real-time quantification assay to detect and monitor BRAF V 600 E mutations in hairy cell leukemia (2012) (0)
MOLECULAR PATHOGENESIS OF HEMATOLOGIC MALIGNANCIES Introduction: Molecular Pathogenesis of Hematologic Malignancies (2012) (0)
Applicability of FLT3-Length Mutations in Exon 14 as a Follow up Marker in AML: An Experience of 148 Cases and 517 Follow up Samples Using Conventional and Real Time PCR. (2004) (0)
Array Based Comparative Genomic Hybridization Detects Copy Number Alterations in 80.3% of Adult Acute Lymphoblastic Leukemia (ALL) with Normal Karyotype or Failed Chromosome Banding Analysis and Identifies a Subset with Only Submicroscopic Alterations Associated with Favorable Outcome (2014) (0)
A Case of Myelodysplastic Syndrome with a Translocation t(1;12)(p36;p13) (2011) (0)
Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms (2022) (0)
Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity (2013) (0)
[Molecular classification in leukemias using gene expression profiling]. (2004) (0)
Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage (2021) (0)
Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration (2022) (0)
High Frequency of AML1/RUNX1 Mutations in Specific Cytogenetic Subgroups in De Novo Acute Myeloid Leukemia. (2007) (0)
Rapid Kinetic RT-PCR Quantification of CBFβ-MYH11 and AML1-ETO Translocations in Acute Myeloid Leukemia Research Samples (2002) (0)
5q Deletions Can Be Identified Based on the Expression Level of 5q Genes: A Study on 49 Cases with MDS or AML Analysed in Parallel by Gene Expression Profiling and Genomic Arrays. (2006) (0)
The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1). (2009) (0)
P040 Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetic, and clinical data (2009) (0)
Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10) (2022) (0)
Die Zukunft der Diagnostik in der Hämatologie (2012) (0)
Analysis of the IDH1G105 (SNPrs11554137) Polymorphism in 961 AML Patients and in a Large Cohort of 475 Healthy Controls (2011) (0)
Acute Monoblastic/Monocytic Leukemia and Chronic Myelomonocytic Leukemia Share Common Immunophenotypic Features but Differ in the Extend of Aberrantly Expressed Antigens and the Amount of Granulocytic Cells. (2009) (0)
ALL-276: Complex Karyotype with ≥3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) (2020) (0)
High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1 mut, MLL -PTD and FLT3 -ITD and Is Useful for Disease Monitoring (2012) (0)
Microarray-Genexpressionsanalysen in der Leukämiediagnostik (2006) (0)
[An endodermal sinus tumor (yolk sac tumor) of the anterior mediastinum]. (1990) (0)
Ubiquitously Expressed Micro RNA miR-16 Is Not Mutated and Not Differentially Expressed in Patients with B-CLL. (2006) (0)
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL). (2012) (0)
[IgD plasmacytoma]. (1984) (0)
Mutations In SETBP1 Occur In 3.1% Of De Novo AML and Show a Distinct Genetic Pattern That Highly Resembles Atypical CML (2013) (0)
TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by rebalancing GATA2 expression (2023) (0)
Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification (2022) (0)
Targeted Next-Generation Sequencing (NGS) Enables for the First Time the Detection of Point Mutations, Molecular Insertions and Deletions, as Well as Leukemia-Specific Fusion Genes in AML in a Single Procedure. (2009) (0)
Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease (2019) (0)
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway (2021) (0)
Abstract 2450: Mutational profiling of MLL-PTD acute myeloid leukemia (2017) (0)
Depletion of the TP53 Family Member p73 Sensitizes Cancer Cells towards Cytarabine. (2012) (0)
Genetic Profiling of Adult Acute Lymphoblastic Leukemia Cells by Single Nucleotide Polymorphism Oligonucleotide Microarray. (2007) (0)
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: BEYOND DDX41: DDH AND DHX HELICASES ARE MUTATED IN MDS (2023) (0)
Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes (2022) (0)
STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia (2022) (0)
High Incidence of RAS Signalling Pathway Mutations in MLL–rearranged Acute Myeloid Leukemia (2012) (0)
NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis (2018) (0)
Überwiegen mononukleärer rund-ovaler Zellen (2002) (0)
Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q) (2021) (0)
Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML). (2006) (0)
Screening for Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients with Cytopenia and Suspected Myelodysplasia Using the Fluorochrome-Conjugated Derivative of Aerolysin, FLAER (2008) (0)
Genexpressionsanalysen bei akuten Leukämien: Diagnostik der Zukunft? / Gene expression profiling in acute leukemia: diagnostics of the future? (2004) (0)
Molecular Characterization of Acute Myeloid Leukemia (AML) Patients Who Relapse More Than 3 Years after Diagnosis: An Exome Sequencing Study of 31 Patients (2018) (0)
F3AK treatment of aggressive lymphoma cells results in induction of apoptosis in vitro (2022) (0)
The Gene Expression Profile in CLL Better Reflects the Igvh-Mutational Status Than the Most Common Chromosome Aberrations. (2004) (0)
Complete hematologic response to sunitinib in an eosinophilia-associated chronic myeloproliferative disorder with an ETV6-FLT3 fusion gene (2007) (0)
Comprehensive Analyses of Mantle Cell Lymphoma with a 17 Gene Panel Reveal an Accumulation of TP53 Mutations in SOX11 Negative Patients (2014) (0)
Complexity of CEBPA Mutated Acute Myeloid Leukemia (2014) (0)
The diverse landscape of fusion transcripts in 25 different hematological entities (2020) (0)
Zytologie von Pleuraergüssen und Aszites (2002) (0)
Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients (2022) (0)
Molecular Analysis of Myelodysplastic Syndrome with Isolated Del(5q) Reveals a Broad Spectrum of Clinically Relevant Mutations: A Study on 119 Patients and 26 Genes (2014) (0)
Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies (2022) (0)
An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival (2015) (0)
Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights (2016) (0)
Long Intergenic Non-Coding RNAs Unambiguously Classify AML Subgroups (2018) (0)
5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap (2014) (0)
An efficient computational approach to evaluate the expression profile of individual acute leukemia patients (2015) (0)
Response to Imatinib Mesylate In CML Patients as Assessed by Quantitative Real Time PCR Can Predict the Probability for Resistance Mutations In the BCR-ABL1 Kinase Domain. (2010) (0)
BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia (2015) (0)
Myeloische und lymphatische Neoplasien mit Eosinophilie und Anomalien von PDGFRA, PDGFRB, FGFR1 oder mit PCM1-JAK2 (2020) (0)
transcripts CBFBMYH11+ acute myeloid leukemia based on quantification of fusion New score predicting for prognosis in PML-RARA+, AML1-ETO+, or (2013) (0)
Punktionstechnik und Zellpräparation (2004) (0)
BCL-2 Inhibition by ABT-199 Potently Induces Cell Death in MDS Progenitors Despite High-Risk Mutations in ASXL1, RUNX1, TP53 or EZH2 (2017) (0)
Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1 (2013) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (2022) (0)
Analysis of SF3B1 in a Large Cohort of Refractory Anemia with Ring Sideroblasts with/without Marked Thrombocytosis (RARS-T/RARS) in an European Multicentre Study Reveals a High Incidence (86.3%) of Mutations and an Independent Favorable Association with Outcome (2012) (0)
The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Torsten Haferlach?

Torsten Haferlach is affiliated with the following schools:

Humboldt University of Berlin
University of Cologne
Kiel University
Hannover Medical School

Torsten Haferlach's Academic­Influence.com Rankings

Why Is Torsten Haferlach Influential?

Torsten Haferlach's Published Works

Published Works

What Schools Are Affiliated With Torsten Haferlach?

Torsten Haferlach's AcademicInfluence.com Rankings